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Located in a schizophrenia susceptibility locus on chr8p21, 
DPYSL2 has been implicated in schizophrenia by numerous linkage and 
association studies; however research on its biology in relation to the risk 
for SZ has been sparse. DPYSL2 encodes CRMP2, a protein that 
functions in axon growth and maintenance. A first targeted sequencing 
study of this gene revealed several non-coding variants that altered 
expression in transient transfection assays. Most interestingly, a 
polymorphic CT di-nucleotide repeat (DNR) variant located in the 5’-
untranslated region of DPYSL2 is associated with SZ risk and disrupts 
regulation of the gene by mTOR signaling pathway. Given the biological 
relevance of DPYSL2 to schizophrenia, the aim of my thesis, composed of 
three separate investigations, was to further explore the molecular 
mechanisms on which variations in DPYSL2 contribute risks for SZ.  
Methods 
 I extended the sequencing screen of this gene on a larger scale 
using a high-throughput pooling strategy, with the goal to identify rare 
functional variants in DPYSL2. The targeted regions for sequencing 
included the 14 exons and 27 conserved noncoding regions in and 
around this gene. To expand our knowledge on the polymorphic DNR 
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variant, we performed protein-RNA interaction studies that identified 
differential binding of mTOR effectors to the DNR alleles. And to study 
the DNR variant in its native genomic context, we used CRISPR/cas9 
genome editing to create two isogenic cell lines that differ only at the 
DNR locus. To study loss of function of Dpysl2 in vivo, we created a 
conditional knockout mouse model of Dpysl2 to test the hypothesis that 
loss of function of Dpysl2 alters axonogenesis, perturbing morphological 
and behavioral phenotypes.  
Results 
From the extended sequencing screen of this DPYSL2, we identified 
a total of 286 variants, of which 66 were novel, and 8 were synonymous. 
The resulting comprehensive variant catalogue of this gene showed a 
modest enrichment of rare variants in SZ patients with no functional 
biases. Because the enrichment was small (1.28 fold-change) and not 
variant-specific, we decided to pursue the aforementioned DNR variant 
instead. In protein-RNA interaction studies, we observed differential 
bindings of proteins to the DNR alleles. Specifically, the longer risk allele 
lost binding to ELAVL4/HuD, a neuronal ribosomal binding protein 
regulated by the mTOR pathway. Additionally, the risk allele also had 
decreased binding to two mTOR effectors, 4E-BP and eIF4E. In the 
CRISPR-edited cells that carry the homozygous DNR alleles, we showed 
that the longer CT repeat leads to significant reduction of CRMP2 levels, 
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accompanied by striking shortening of cellular projections, and 
significant transcriptome changes that link this transcript back to SZ. 
We also successfully created a conditional Dpysl2 knockout mouse, 
which shows interesting phenotypic changes in preliminary behavioral 
tests. The results will be confirmed and extended with additional testing, 
and this mouse model has the potential to be a powerful tool in the study 
of SZ.  
Conclusion 
Together my work contributes a significant body of evidence that 
link DPYSL2 and mTOR to risk for schizophrenia. My results support the 
functional importance of the DNR, suggest a role for mTOR signaling, 
and further implicate DPYSL2 as a schizophrenia susceptibility gene. 
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Schizophrenia (MIM #181500), henceforth referred to as “SZ,” is a 
common and disabling neuropsychiatric disorder that can alter a 
person’s thought and cognitive awareness. The disorder affects as much 
as ~1% of people worldwide, and causes a wide range of cognitive 
symptoms in early adulthood that can severely impair many facets of 
ordinary life 1. In addition, SZ causes a huge economic burden, costing in 
excess of $62 billion in 2002 for the United States alone 2. Despite the 
clinical, social, and financial impacts of SZ, the etiology of the disorder 
remains elusive though evidence suggest a strong genetic component 3. 
Twin and adoption studies suggest that SZ is highly heritable, with 
concordance rates ranging from 40-65% for monozygotic twins and 5-
15% for dizygotic twins 4. Furthermore, adoption studies implicate 
shared environment as contributing risk factors for developing SZ 5,6.  
DPYSL2 as a SZ susceptibility gene 
 
Genome wide linkage scans and candidate gene association studies 
have revealed a number of SZ susceptibility genes 7,8, including DTNBP1 
(MIM *607145), DISC1 (MIM *605210), NRG1 (MIM *142445), and NRG3 
(MIM *605533). In particular, through one of the largest SZ SNP-based 
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linkage studies to date, our group identified region 8p21-22 as a 
candidate SZ susceptibility locus (p=0.0001) 9. Our result was replicated 
by many other groups in different population 10–12, and we later 
performed a candidate gene-based association study targeting the 8p21 
region in the Ashkenazi Jewish population 13. We found the strongest 
linkage evidence over SNP rs12155555, located ~5 kb upstream of 
DPYSL2, and the strongest association signals from the follow-up fine 
mapping were located within or flanking the DPYSL2 gene 13. 
The dihydropyrimidinase-like 2 gene (DPYSL2) encodes a 62kDa 
cystolic protein best known as collapsin response mediator protein 2 
(CRMP2), a member of a 5-gene family named for their involvement in 
axonal growth cone collapse. Mammals express three different 
transcripts of DPYSL2: A, B and C, each differing in the alternative first 
exon. Nearly all published literature has centered on the B transcript, 
which is also the transcript of this investigation, and is henceforth 
referred to simply as DPYSL2. Located at 8p21.2 (26.5 Mb), DPYSL2 is 
primarily expressed in the central nervous system, though it is also 
found at lower levels in the peripheral nervous system 14. This gene is 
reported to have vital functions in neuronal development 15–18, with 
dysfunctions resulting in neurodevelopmental abnormalities, which may 
be a contributing factor in the pathogenesis of SZ. Knockout mutants of 
CRMP2 display abnormal dendritic formation in hippocampal cells, 
suggesting that CRMP2 is essential for proper dendritic organization 19. 
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Further, aberrant expression of DPYSL2 has been reported in multiple 
areas of the SZ postmortem brain, including the hippocampus 20, the 
frontal cortex 21, the anterior cingulate cortex 22, and the dorsolateral 
prefrontal cortex 23. The CRMP2 protein interacts with other proteins to 
stabilize microtubules, promote neurite outgrowth, and modulate 
signaling processes in the central nervous system 24–27. In cell culture 
studies, altering the expression of Crmp2 significantly affected the axonal 
growth of rat hippocampal neurons 19,28. Most recently, a study showed 
downregulation of Crmp2 protein in the prefrontal cortex and 
hippocampus of rats that were stressed prenatally 29. The study also 
identified 2 SNPs that were associated with schizophrenia susceptibility, 
further suggesting a role for DPYSL2 in this disease 29. 
Initial sequencing study of DPYSL2 
 
In a previous study 30, we sequenced 137 SZ patients and similar 
number of controls and identified 120 variants, some of which were 
significantly associated with SZ. Several of these are in conserved non-
coding regions (cNCRs) and show sex-specific risks for SZ with odds ratio 
of 2 – 2.5 in one sex but not the other. Additionally, a few variants in the 
promoter region and intron 1 of DPYSL2 showed evidence of directing 
expression patterns in the central nervous system when expressed in the 
zebrafish, pointing to the regulatory potential of these variants. Most 
interestingly, the study identified a polymorphic CT di-nucleotide repeat 
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(DNR) located in the 5’-untranslated region (UTR) of this gene 30. The 
DNR disrupts a reported 5’-terminal oligopyrimidine tract (5’-TOP), a 
consensus sequence marked by a Cytosine that preceeds a continuous 
tract of pyrimidines 30–32. Translation of 5’-TOP mRNAs is thought to be 
regulated by the mTOR pathway 33,34. In their investigation, Liu et al. 
reported 11 CT repeats (11DNR) in the common allele and 13 CT repeats 
(13DNR) for the alternative allele, with the risk allele reducing translation 
by 3-fold in transient expression systems in cells and in polysome 
profiling experiments. Further, we reported a dose-dependent response of 
the two DNR alleles to Rapamycin, an allosteric inhibitor mTOR, 
suggesting regulation of DPYSL2 by the mTOR pathway. This result 
delineates the DNR as a functional genetic variant and suggests a 




 Given the biological relevance of DPYSL2 to schizophrenia, the aim 
of my thesis was to further explore the molecular mechanisms on which 
variations in DPYSL2 contribute risks for SZ. To this end, my thesis is 
composed of three separate but related investigations. First, I tested the 
hypothesis that SZ patients carry more rare functional variants than the 
controls variation in and around DPYSL2. Specifically, I extended the 
sequencing screen of the exons and conserved sequences around this 
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gene on a larger scale, in a more homogeneous population, and with a 
more high-throughput sequencing strategy. In the resulting 
comprehensive variant catalogue of this gene, we found a modest 
enrichment of rare variants in SZ patients with no functional biases. 
Because the enrichment was small (1.28 fold-change) and not variant-
specific, we decided to not follow-up any individual variants from this 
screen.  
Second, I expanded our knowledge on the polymorphic CT DNR 
variant, showing that it perturbs mTOR signaling via differential binding 
of different mTOR effectors. We created isogenic cell lines that differ only 
at the DNR locus, and showed the longer CT repeat leads to significant 
reduction of CRMP2 levels, accompanied by striking shortening of 
cellular projections, and significant transcriptome changes that link this 
transcript back to SZ. The results from this study strengthen the 
evidence that this variant is likely a risk factor for SZ, with the risk allele 
altering cellular phenotypes at the protein, morphology, and 
transcriptome level. 
Finally, we created a knockout mouse model of Dpysl2 to test the 
hypothesis that loss of function of Dpysl2 alters axonogenesis, 
perturbing morphological and behavioral phenotypes. To my knowledge 
at this time, no such mouse model exists for this gene in the C57BL/6 
background. Our preliminary behavioral tests showed possible 
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phenotypic changes in the knockouts, the results of which could be 
confirmed and extended with additional testing. The conditional Dpysl2 
knockout mouse has the potential to be a powerful tool in the study of 
SZ and genetics in general.  
Together my work contributes a significant body of evidence that 
link DPYSL2 and mTOR to risk for schizophrenia. My results support the 
functional importance of the DNR, suggest a role for mTOR signaling, 




Figures: Chapter 1 
 
Figure 1.1: Schematic of the 5'-TOP tract of DPYSL2 
 
Figure 2.1: The polymorphic CT di-nucleotide repeat (DNR) variant is 
located in the 5’ UTR of DPYSL2, which is also part of a reported 5’-
terminal oligopyrimidine tract (5’-TOP), a consensus sequence defined as 








Linkage and association studies have repeatedly implicated 
DPYSL2 on chr8p21 as a candidate gene for SZ; however, no causal 
variants have been identified. DPYSL2 encode CRMP2, which is 
important in axonal growth, and dysfunction of this gene may result in 
neurodevelopmental abnormalities. In a first targeted sequencing study 
of this gene, we previously identified several non-coding variants in and 
around DPYSL2 that altered expression in transient transfection assays. 
In order to capture more rare and functional variants in DPYSL2, we 
extended the sequencing screen by using a high-throughput strategy in a 
homogenous AJ population. We included all known DPYSL2 exons and 
alternative exons as well as conserved non-coding regions within and 
around the gene. Our screening strategy identified 286 variants, of which 
97% are non-coding and 24% are unannotated. With a comprehensive 
catalog of genetic variation at this locus, we found a modest enrichment 
of multiple rare variants in SZ cases compared to controls, though the 
variants did not show regulatory biases. In addition, two synonymous 
rare variants did not show exonic splicing potential in carrier 
lymphoblasts. Our results suggest variants at this locus could contribute 
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risk for SZ, though additional work is needed to follow up the specific 





Our group was among the first to report strong linkage evidence for 
region 8p21 (27.61 Mb; 1-LOD interval 21.37-29.36 Mb) to SZ in both 
European Caucasian (EUC) and Ashkenazi Jewish (AJ) populations 9. 
Since then, this linkage peak has been replicated by multiple groups in 
different populations, all converging on region 8p21 as a possible SZ 
susceptibility locus (SSL) 7,10–12,35,36. Our group has investigated this 
8p21 region in two ways: first, a family-based association study in 106 of 
our 8p-linked EUC families using 1402SNPs distributed across a 4.4 Mb 
interval (24.8-29.2 Mb) centered on the peak; and second, an 
independent case-control association study in a genetically more 
homogeneous AJ sample (709 cases, 1547 controls). In the EUC all SNPs 
with nominally significant associations contained in an 2.8Mb region 
(25.7-28.5 Mb) were selected for further study using 970 SNPs in our AJ 
case/control study. The strongest signal in the latter was for rs12155555 
(OR = 0.66; CI: 0.53-0.81, p=0.00006) located about 3 Kb 3’ of DPYSL2 
and the 9 SNPs with best p values are all located in the 256 Kb interval 
between the telomeric (PNMA2) and centromeric (ADRA1A) neighbors of 
DPYSL2 13. 
To search for possible causative variants driving the linkage and 
association in this region, we have previously conducted targeted 
sequencing of the 14 exons and 27 conserved non-coding regions 
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(cNCRs) in and around DPYSL2. This was done in a small sample set (48 
EUC and 89 AJ SZ probands, and 96 EUC and 56 AJ controls) 30. This 
study identified 120 sequence variants, 38 of which were not in dbSNP 
(build 129); 30 of these had a MAF <1%. Of 10 coding variants, 9 were 
synonymous and one was a novel missense allele, A267S, present in a 
single EUC SZ proband. Several of these are in conserved non-coding 
sequences (cNCS) in the promoter region and intron 1 regions, which 
showed direct appropriate CNS expression pattern when expressed in 
zebrafish. Several of the human DPYSL2 variants show sex-specific risks 
for SZ with OR of 2-2.5 in one sex but not the other. All of the risk alleles 
cause reduced expression in transient transfection assays in 293 cells 
and mouse primary cortical neurons. Most importantly, we identified a 
polymorphic dinucleotide variant (5’DNR) in the 5’UTR of DPYSL2 that 
disrupts a 5’TOP sequence. The risk allele of this variant reduces 
translation by 3-fold in transient expression systems in cells and in 
polysome profiling experiments 30. Taken together, these results add 
further evidence of significant association of SZ with SNPs in and around 
DPYSL2. 
Spurred by the preliminary sequencing results, which were done in 
a small cohort of patients and controls, we embarked on a task to extend 
the sequencing efforts beyond what we previously reported. Specifically, 
our goal was to screen DPYSL2 on a larger scale in a more homogeneous 
population using a more high-throughput sequencing strategy, with the 
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idea that this will allow us to capture more rare and functional variants 
in this gene. We hypothesized that SZ patients carry more of these rare, 
functional variants than the controls. Furthermore, by expanding our 
search for causative variants, we expected this would provide insight into 
how alterations in DPYSL2 and its protein product, CRMP2, contribute 
risk for SZ.  
To do this, we performed next-generation sequencing (NGS) of 
DPYSL2 in 768 total of Ashkenazi Jewish patients and controls, targeting 
the same regions as the previous study, which included 14 exons and 27 
conserved noncoding regions. Using a pooling strategy and next-
generation sequencing, my screen identified 286 single nucleotide 
variants, the majority of which were non-coding. We tested this catalogue 
of variants for enrichment of rare functional variants between the two 
groups, and found a small, statistically significant enrichment for the SZ 
cases. Specifically there was about 1.3 fold more rare alleles in cases 
than in controls when the allele frequency less than 1%. We also 
explored whether variants that are enriched in SZ cases had more 
regulatory features, and found no significant overlap compared to those 
found in controls. In addition, we followed up two synonymous variants, 
which were predicted to alter binding of splicing factors. However, in 
testing DPYSL2 splicing pattern of carrier vs. non-carrier lymphoblasts, 
we found the variants do not alter splicing of the exons in DPYSL2. Our 
results indicate that DPYSL2 potentially harbors rare variants that occur 
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more often in SZ cases; however, the significance of this weren’t striking 
enough to pursue follow-up of variants for individuals in the pooled 
screen.  
 




The sample set in this study included 384 unrelated Ashkenazi 
Jewish (AJ) cases and 384 AJ controls, which were from the extensively 
phenotyped sample assembled and characterized by Dr. Pulver and her 
team 37. All SZ cases where diagnosed based on DSM-IV criteria for 
schizophrenia or schizoaffective disorder 36. All controls were screened 
for negative history of psychotic episodes, psychiatric hospitalization, 
and other SZ-relevant symptoms. Samples were collected with informed 
consent under the approval of the Johns Hopkins Institutional Review 
Board.  
Identification of Regions of Interest 
 
At the time of my sequencing studies, there was little evidence 
about DPYSL2A or DPYSL2C, so I focused exclusively on the B isoform, 
excluding the alternative first exons of the A and C isoforms. The regions 
of interest included the 14 known DPYSL2 exons as well as 27 conserved 
non-coding regions (cNCRs) in and around the gene, as described 
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previously 30. The cNCRs were selected on the basis of sequence 
conservation and computational prediction of enhancer elements 30.  
Pooling and Next-Generation Sequencing  
 
We used a pooling and next generation sequencing strategy 38 to 
quickly and cost-effectively sequence all the regions of interest in 
DPYSL2. DNA concentrations were obtained for each sample using a 
PicoGreen dsDNA assay. The samples were normalized and combined 
into pools, each containing 32 samples. This yielded an even 12 pools for 
cases and 12 pools for controls. Next, the 14 exons and 27 cNCRs were 
PCR amplified, which resulted in 46 high quality amplicons that covered 
36.9 kb of DPYSL2 (Table 2.1). The amplicons from the same pool were 
combined at equal molar ratio, resulting in 24 pools with 46 amplicons 
per pool. The pooled amplicons were ligated to avoid "end" enrichment 
effects, blunted and randomly fragmented using NEBNext dsDNA 
Fragmentase (NEB # M0348S). This fragmented DNA was then used to 
generate 24 indexed libraries using Illumina’s TruSeq DNA Sample 
Preparation v2 Kit (Illumina # FC-121-2001, 2002).  Indexed libraries 
were quantified and pooled together at equal molar ratio. The indexed 
libraries were run in one lane on our HiSeq 2000 genome analyzer in our 




Sequencing analysis  
 
The paired reads were treated as single reads due to the nature of 
this experiment. The sequences were aligned and indexed to the 
reference genome (GRCh37/hg19) using Bowtie and SAMTools software. 
We used the Integrative Genome Viewer 2.0 (IGV) to visualize our reads 
and to identify variants. Because the frequency of one variable allele in a 
pool is very low (~1.56%), we improved sensitivity by also employing an 
automated system of variant selection in order to capture possible 
variants that might have been missed with IGV. We generated Perl 
scripts to sort through alignments and identify bases that were read as 
different nucleotides 0.5% of the time or more (expected alternative allele 
frequency in a pool with 1 heterozygote is 1.56%) taking into account 
information on strand bias. The total number of variants identified was 
286 (Table 2.2). 
Variant Filtering and Selection 
 
From the total list of identified variants, we explored whether there 
was an enrichment of rare functional variants in the cases vs. the 
controls. To do this, we filtered the variants to select for those that had 
an MAF < 10% as reported by dbSNP. Variants that were novel and not 
catalogued by dbSNP were included in this set, as these were assumed to 
also be low in frequency by inference. Using the USCS Genome Brower 
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software, we also selected variants that were conserved and had 
regulatory features, defined by evidence of CpG islands, transcription 
factor binding sites, methylation features (H3K4me1, H3K4me3), 
acetylation features (H3K27Ac), and DNase hypersensitivity. These 
criteria filtered the 286 variants to a short list of 68 variants (Table 2.3). 
For each of the 68 variants, the estimated allele counts were calculated 
using the reported IGV allele frequencies for the case or controls, 
multiplied by 64 (the number of chromosomes per pool) and multiplied 
by 12 (the total number of pools for cases or controls). The total 
estimated allele counts for the cases and controls were compared for 
evidence of enrichment in either group using the chi-square test.  
The 68 variants were then separated into those that were enriched 
in cases (n = 31) vs. those not enriched in cases (n = 37). For each 
subset, I compared the number of variants that overlapped with the 
regulatory features as described above.  
Testing 2 synonymous variants for splicing potential 
 
 The synonymous variants (known: rs113199330 and novel at chr8: 
26,484,146) were predicted by ESEFinder 3.0 to alter binding of 
serine/arginine-rich splicing factors (SRSF), which could affect the 
splicing patterns of DPYSL2 39. To test this potential, we assayed 
DPYSL2 transcript expressions in non-carrier vs. carrier lymphoblasts, 
which were identified by de-convoluting the pools containing the 
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variants. We obtained lymphoblast cultures from 6 Ashkenazi Jewish 
samples that were sequenced, 2 were carriers for the variants, and 4 
were non-carriers, as well as 2 additional samples that were not AJ. 
From the lymphoblast pellets, we isolated RNA (Qiagen #74104) and 
synthesized cDNA using SuperScript III RT-PCR kit (Invitrogen 
#12574018). The cDNA was used as the template for PCR with primers 
specific at exon 3 and exon 6 of DPYSL2. The reaction was performed 
under standard PCR conditions, and products were visualized on 1% 




High coverage of mappable reads 
 
Using the pooling strategy and next-generation sequencing, we 
received over 384 million 75 bp paired-end reads. The distribution of 
reads ranged from 9.7 to 27.3 million reads, with an average of 16.3 
million reads across the 24 pools. In comparing the distribution of reads 
for cases vs. controls, the differences are not statistically significant (p = 
0.054) (Fig. 2.2). The reads had > 80% alignment to the reference genome 




Majority of variants identified are non-coding 
 
Using both the manual and automated methods of variant 
classification, we identified a total of 286 single nucleotide variants 
(SNVs): 8 (~3%) are synonymous coding variants, and 278 (~97%) are 
noncoding (Table 2.2, Fig. 2.3). Of this, 65 variants (23%) were novel. The 
total number of SNVs identified in this study of 768 individuals (384 
cases, 384 controls) is about  ~2x more than the 120 variants identified 
in the first sequencing study of 192 samples 30. In addition, these new 
results verified all the coding variants identified in the prior sequencing 
study. 
 
Mild enrichment of rare and functional variants in SZ cases vs. 
controls 
 
 In comparing the variable allele counts between cases and 
controls, we found a small enrichment of rare variants in SZ cases vs. 
controls. Specifically, there was about 1.3 fold more rare alleles in cases 
than in controls when the allele frequency was less than 1% (p = 4 x 10-
4). This was the highest fold change, as at an allele frequency of 10%, the 
enrichment was reduced to 1.08 fold (p = 5 x 10-4). The enrichment was 
non-significant when we compared between allele frequencies of 2% and 
5% (p > 0.1) (Table 2.4). In addition, when we assessed whether variants 
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that are enriched in SZ cases have more regulatory features, we found no 
significant overlap compared to those found in controls.  
Two synonymous variants do not alter DPYSL2 splicing  
 
Our selection criteria included 2 synonymous variants, one known 
(rs113199330) and one novel (chr8: 26,484,146). These variants were 
analyzed for splicing potential using the Exonic Splcing Enhancer Finder 
(ESEFinder 3.0) 39, which reported alterations in loss and gain of several 
serine/arginine-rich splicing factors (SRSF) for both SNPs (Fig. 2.4A). In 
RT-PCR assays that tested splicing potential of the two synonymous 
variants in lymphoblast tissues, we identified a singular amplicons band 
at the expected size (~480 bp) for both carrier and non-carrier samples 
(Fig. 2.4B). This indicated that the two synonymous variants do not 




In this part of my thesis, our aim was to expand our search for 
causative variants on the rationale that this will provide insight into how 
alterations in DPYSL2 contribute risk for SZ. We did this by performing a 
sequencing screen in a homogenous AJ population using a high-
throughput strategy that quickly and cost-effectively captured all the 
regions of interest in the DPYSL2. Our pooling technique proved that 
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parallel sequencing is an effective method for deep coverage of a region of 
interest in many samples, as we obtained high coverage of every 
amplicon with thousand of reads covering the vast majority of the 
targeted regions. However, we noted that with 32 people per pool, the 
expected frequency of one variable allele per pool is very low (~1.56%) 
and close to the 1% due to background noise. To increase signal and 
better identify true positives, we recommend reducing the pool size to 16 
people or less. 
The result of this effort is a new comprehensive catalogue of 
variants in and around the DPYSL2 gene for well-researched 
homogenous AJ population. Overall, the paucity of synonymous variants 
(3% from total of identified variants) is remarkable and indicates that 
DPYSL2 is highly conserved has strong biological relevance. By keeping 
the cases and controls separate, we could estimate whether certain 
variants are more common in one vs. the other group. This analysis 
yielded a small, statistically significant enrichment of rare variants in SZ 
cases vs. controls, a result that’s interesting and supports our 
hypothesis that SZ patients are predisposed for more variants. However, 
the enrichment is small, is spread across all reads, and do not point to 
any one particular variant. Furthermore, when we looked to see if 
variants that are enriched in SZ cases have more regulatory features, we 
found no significant overlap compared to those found in controls. In 
analyzing two coding variants of this list that were predicted to alter 
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binding of splicing factors, we determined that these synonymous 
variants do not influence exon splicing of DPYSL2 in lymphoblasts. 
Overall, my results for this study are promising, as the catalogue of 
variants could have high utility with more advanced techniques such as 
massively parallel reporter assays, which can simultaneously test all of 
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Table 2.1: DPYSL2 sequencing primers 
Primer ID Sequence Product (bp) 
   
DPYSL2 E1 F AATCGCTGCTCGTCTCTCTC 554 
DPYSL2 E1 R AGTTCGGTCCCTCTCCTTTC  
   
DPYSL2 E1 F' ATTTGCATATCCCAGGATCG 364 
DPYSL2 E1 R' GACCGCAGATTTCCCAAGTA  
   
DPYSL2 E2 F GGTTGCCACATACAGGCTTA 393 
DPYSL2 E2 R TGGTCACTCTCTGATGTTCCTG  
   
DPYSL2 E3 F GCACAGAGCGGAGGATAGTT 376 
DPYSL2 E3 R GTGGCTCAGGACAGCAAGTT  
   
DPYSL2 E4 F CGATTTTGAACCCAAGAAGC 425 
DPYSL2 E4 R ACAAATGGGATCTGGAAGCA  
   
DPYSL2 E8 F CAGCCTCGCCTTCATCTTAG 421 
DPYSL2 E8 R ATACTAACAAGGCCGCAGCA  
   
DPYSL2 E9 F TCTGCGAGATGAGCCTGATA 418 
DPYSL2 E9 R TTTGGTGAACAAGGGTCTCC  
   
DPYSL2 E10 F GGGAGGGGATTCTGGATAAA 436 
DPYSL2 E10 R TGTCATTTCAAGGCCTCCAT  
   
DPYSL2 E11 F CAACGCTCTTGACATCCATC 428 
DPYSL2 E11 R CCCAGCAAATTGCAAATCAT  
   
DPYSL2 E12 F CAGGATCCCTGTCTCTGAGTCT 432 
DPYSL2 E12 R GCTCCCTCTTATCCCTGGAA  
   
DPYSL2 E13 F CACACAACACCTGTCCACCT 435 
DPYSL2 E13 R CACGTTGGAGAGAAAGGGAAT  
   
DPYSL2 E14 F GCACTTTTCCTCCTGAGCTG 551 
DPYSL2 E14 R GGTGGGTAGTCTTGGGTGTG  
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DPYSL2 E5-7-1 F1 TGCTTCCTTTACCATTCTGTG 551 
DPYSL2 E5-7-1 R1 AAGCTCTTGGGTGACACCTG  
   
DPYSL2 E5-7-2 F CGGCACTCAGAACCTCCTTA 493 
DPYSL2 E5-7-2 R ACCAGGTCCCTCTGCTTTTC  
   
DPYSL2 E5-7-3 F CAGGGCTTTCTTTTTCGTCA 533 
DPYSL2 E5-7-3 R ATTTTGCACAGCTCTGATGG  
   
DPYSL2 E5-7-4 F GAACGATCGGCAGTGGTAAT 412 
DPYSL2 E5-7-4 R ATCTTCTGGCGAAACAGTCC  
3prime_cNCR1_1_F CTGCACCCAGTGATGTGTGT 2218 
3prime_cNCR1_2_R TGCTGTTGTCCTCTGTGAAAA  
   
3prime_cNCR2_F AGGCAGCACCAGGAAGAGT 517 
3prime_cNCR2_R CTGGCTTTTGATCTCGGTTC  
   
3prime_cNCR3_1_F1 GAGTTTGCCTCTGGGAAGTG 870 
3prime_cNCR3_2_R CTGTGGTCGACAGCACCTTA  























   
DPYSL2 5'-1 F CTCAGGGCTCTCATTTCCTG 715 
DPYSL2 5'-6 R GAGAGAGACGAGCAGCGATT  
   
DPYSL2 5'-2 F ACGACCACCCCTCCATTGT 352 
DPYSL2 5'-2 R GGAAGGGGGTGGAAATAAAC  
   
DPYSL2 5'-3 F CCAGCCACCTTTTGTAGCAC 503 
DPYSL2 5'-3 R AGCATCCCTCTGCTGTCATT  
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DPYSL2 5'-4 F CTGGGCAGTCAGGACACTCT 489 
DPYSL2 5'-4 R GAAATGAGAGCCCTGAGGAA  
   
DPYSL2 5'-5 F AGATGGGGACTTGGATCCTC 608 
DPYSL2 5'-5 R GAGAGGTGGGAGCAAGACTG  
   
DPYSL2 U1-1 F CTGCAGTGAGCCGAGATTTT 2410 
DPYSL2 U1-6 R TGCATTAACGGTCTTCCTACTG  
   
DPYSL2 U2-F1 CCCATCCATCAGCTCACAC 645 
DPYSL2 U2-4 R CCTAAGTCTCCCTCGCTGTG  
   
DPYSL2 U3-1 F TACTGGAGCAGAAGCCCACT 1409 
DPYSL2 U3-4 R GACCACCAGGCTCAAGTGAT  
   
I3_cNCR1_F AAATCACATGGTCCCAGCAC 530 
I3_cNCR1_R2 CCCGTGTCCTTAGGAGAAATG  
   
I3_cNCR2_1_F CCCCAAGCTGACCTTTCTCT 1234 
I3_cNCR2_2_R CACGCTCAGACAGAAAGCAC  
   
I3_cNCR3_F GCATTCAAATGAGGCCAACT 3184 
I3_cNCR3_R TCAGGAGATGGAGAGGAGGA  
   
I3_cNCR4_1_F GAGGGATACTTTGCATCTGGA 1938 
I3_cNCR4_2_R TCCCAACAGAATGTATCAGGAA  
   
DPYLS2_cNCS1_R TGGGTGTCCTGACTGGCTAT 509 
DPYLS2_cNCS1_F_OUT TGACTTCTTGGGTGTCCTGA  
   
DPYLS2_cNCS2_F GATGAACCGGAGTGGTTTGT 555 
DPYLS2_cNCS2_R TCCAAGCTGGAATTTGATCC  
   
DPYLS2_cNCS3_F CTGTCCATCCCAGTTGGTTT 599 
DPYLS2_cNCS3_R CAGGCCTCTACCTCCACAAG  
   
DPYLS2_cNCS4_F_OUT CTGTATCTCTGGGAGGTGCTG 350 
DPYLS2_cNCS4_R_OUT CCTTGTCTCCACCAGAGCTT  



















































   
3prime_cNCR2_F AAGCATTCTCTGTGGGAGTCA 399 





Table 2.2: List of 286 SNVs identified through sequencing screen 
Variant 
Coordinates 
Ref / Alt. 
Allele 
Known SNP 
26366941 A/G rs59632294 
26367091 G/A NO 
26367158 G/A NO 
26371264 G/A rs117982477 
26371438 T/C NO 
26371543 C/A rs17403251 
26371729 C/G NO 
26371793 T/C rs17055370 
26372335 C/T NO 
26372351 A/G rs149517015 
26372354 G/A NO 
26372358 G/A NO 
26404953 T/C rs192158859 
26404960 G/A rs9314324 
26404986 A/C rs73226141 
26405024 G/A rs13279683 
26405185 G/T rs78025765 
26405344 A/T NO 
26405508 G/T rs7831864 
26405630 C/G rs12548421 
26405639 G/A rs12543392 
26405691 G/A rs12543398 
26405745 T/C rs77020974 
26405755 G/A rs79293718 
26405918 G/C rs7823093 
26406022 G/C rs10110479 
26406093 T/C NO 
26406095 A/G rs182669480 
26434583 A/G NO 
26434626 C/G NO 
26434795 C/G rs431246 
26434888 G/A NO 
26435116 C/G rs367948 
26435123 T/C rs400181 
26435129 C/A rs76729423 
26435213 C/G NO 
26435238 G/T NO 
26435271 T/C rs445678 
26435451 C/T rs114900295 
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26435549 DNR rs3837184 
26435691 C/A NO 
26436000 T/A NO 
26436034 A/G rs74917054 
26436109 T/C rs379266 
26436221 G/A NO 
26436344 T/A NO 
26436349 A/G NO 
26436349 A/G NO 
26436351 G/A NO 
26436480 C/G rs67474860 
26436481 C/G rs35321818 
26436576 G/C rs11781865 
26436620 G/A NO 
26436770 G/A rs2584184 
26436783 G/A  rs62491888 
26441264 T/C NO 
26441275 G/A rs415524 
26441477 G/A rs11786691 
26441529 G/A rs188964405 
26441562 G/A rs408753 
26447419 C/G rs73226171 
26447481 T/G rs17055482 
26447694 G/T NO 
26447739 G/A rs140053560 
26447767 C/T rs143736793 
26447790 A/G rs62491913 
26447791 T/C rs113140418 
26447830 T/A rs68019818 
26450473 A/G rs7825468 
26450631 T/C rs141355118 
26450858 G/A rs146056239 
26450941 C/T rs77163697 
26450950 G/A rs140047324 
26451098 G/C rs17055487 
26451134 C/G NO 
26452999 A/G rs62491919 
26453039 G/A rs73226176 
26453105 C/T rs5029306 
26453162 G/A rs78609329 
26453220 C/G NO 
26453468 G/T rs11990271 
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26453486 T/A rs114130812 
26453655 G/A rs17055489 
26453830 C/T rs12550663 
26454048 C/T rs17055491 
26454316 C/T rs17055492 
26454793 C/T rs76431903 
26454911 G/A rs17088245 
26455093 C/T rs185303505 
26455100 C/T rs62491920 
26455145 C/T rs181423952 
26455242 G/A rs113220440 
26455403 G/A rs77586745 
26455418 T/C NO 
26455422 A/G rs17406372 
26455439 C/T rs17055494 
26455539 T/A rs117245463 
26455543 G/A rs139911806 
26455566 C/T rs115825436 
26455715 G/A rs327232 
26455800 T/C rs7001738 
26455881 C/T NO 
26455992 T/C rs188591677 
26455992 T/C rs188591677 
26466011 G/T rs74787584 
26466059 T/A rs7820433 
26466520 G/A rs191369930 
26466789 A/G NO 
26466803 C/T rs116834469 
26466860 C/A rs11775967 
26466877 G/A rs62491954 
26467541 C/T rs146182569 
26481666 C/T rs113199330 
26481771 C/T rs327222 
26481822 C/T rs139123217 
26484061 C/T rs112899484 
26484081 G/T NO 
26484146 C/T NO 
26484258 T/C rs192142164 
26484392 C/T NO 
26484404 G/A NO 
26484426 G/A rs77752269 
26484435 G/C rs62493366 
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26484613 G/C rs17322275 
26484652 T/A NO 
26485062 C/T rs327228 
26485063 G/A rs73678824 
26485085 G/A rs112094282 
26485212 C/A NO 
26485243 C/G NO 
26485282 T/C rs41276285 
26485318 C/T rs41276287 
26485346 A/C rs141241578 
26490251 A/G rs753508 
26490251 A/G rs753508 
26490316 C/G rs327217 
26492397 C/T rs78121726 
26492470 G/T rs55906521 
26492529 C/T rs76617667 
26492560 A/C rs1867042 
26497684 A/G rs191998425 
26497820 A/G rs77434938 
26498013 T/G rs13277175 
26498023 G/A NO 
26499118 A/G rs10088957 
26499227 C/T rs327218 
26499331 C/T rs118022714 
26499497 C/T rs62493399 
26501169 C/T rs187445527 
26501179 G/A rs187445527 
26501344 A/G rs184841156 
26501351 A/G rs7841384 
26505135 G/C NO 
26505307 A/C rs139163162 
26506650 A/C NO 
26506809 C/T NO 
26510792 C/T rs708621 
26513312 T/G NO 
26513313 G/T rs73227625 
26513324 T/A rs71216769 
26513364 G/A NO 
26513525 G/A rs76752934 
26513708 T/A rs35314544 
26514054 G/C rs113080437 
26514101 C/T rs58827210 
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26514144 C/T rs17055639 
26514171 G/A rs17055641 
26514231 C/G  rs17055646 
26514293 G/A rs1058332 
26514316 C/T rs11863 
26515005 C/G rs41276289 
26515138 C/T rs45471201 
26515458 T/C rs17666 
26515472 G/A rs10495 
26515560 T/C rs71656236 
26515569 T/C rs35258691 
26515663 G/A rs10042 
26515695 G/A NO 
26515893 A/G rs7827731 
26516038 A/C rs7828056 
26516213 T/G rs7831883 
26518712 A/G rs78578770 
26518714 G/A rs35346375 
26518751 G/T rs7845740 
26518780 G/A rs7842128 
26518854 A/G rs58047393 
26518909 C/T rs57846118 
26518910 T/C rs56322416 
26520560 C/T rs12155555 
26520634 C/T rs6557935 
26535998 A/G rs117181094 
26536126 C/T rs186111033 
26536141 G/A NO 
26536143 G/A rs7831201 
26536337 G/T rs138582766 
26536442 C/T rs73676401 
26550225 C/G NO 
26550278 T/C rs187288868 
26550290 C/T rs112917653 
26550524 G/A rs73678614 
26550553 T/G  rs35568528 
26550576 G/A  rs73678615 
26550621 C/G NO 
26550818 T/C  rs73678616 
26550866 T/C rs73678617 
26551345 C/G NO 
26551397 T/C rs17330796 
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26551416 C/A rs17055703 
26551529 G/A NO 
26558088 C/T rs190695344 
26558113 T/C rs17422356 
26563796 A/G rs17331399 
26564046 T/C rs193051886 
26564049 T/C rs17055758 
26564127 G/T NO 
26564148 C/G rs2044106 
26564172 T/C rs184835321 
26564180 G/A rs144125071 
26564246 C/A NO 
26564320 T/C NO 
26564552 G/A rs182164738 
26564603 C/T rs185508817 
26564629 T/C rs55780663 
26564769 G/A NO 
26564949 A/G rs56315822 
26564953 A/G rs71519610 
26564966 G/T NO 
26565093 G/A rs6985931 
26565139 C/T NO 
26565140 G/A rs116838475 
26565155 C/T NO 
26565230 G/A rs114428764 
26565299 T/A NO 
26565429 C/T rs116510299 
26565510 C/T rs115507492 
26565666 A/G rs191918596 
26565686 A/T rs7007717 
26565770 C/T rs7001655 
26565771 C/A rs115013410 
26565845 T/C rs111568746 
26565846 A/T  rs71553819 
26565854 A/G rs34790461 
26574356 C/A rs79743265 
26576602 C/T NO 
26577021 C/T rs13278281 
26577324 C/A rs139839350 
26577484 C/A NO 
26577645 C/T rs73229635 
26577795 A/T NO 
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26577883 A/G  rs114104363 
26577919 G/T rs994098 
26578017 G/A rs1036813 
26585092 G/T NO 
26585149 G/A rs6998714 
26585177 T/C rs4732831 
26585268 G/A rs10503796 
26585403 G/A rs149880076 
26585513 T/G rs58777446 
26585613 C/T rs1908650 
26585653 C/T rs193100914 
26586503 G/A NO 
26586689 A/G NO 
26586772 G/A rs34099297 
26586846 A/G no 
26586846 A/G NO 
26586846 A/G NO 
26586880 A/G NO 
26586931 C/T rs1317256 
26591848 C/T rs1025860 
26591865 G/A rs186769997 
26591883 C/A rs1025859 
26591911 A/T rs141958536 
26592057 T/C NO 
26592092 G/A rs78167668 
26592119 G/A rs1025858 
26592353 G/A rs2132449 
26592353 G/A rs2132449 
26592504 A/G rs1016734 
26592538 T/C rs76802184 
26592643 G/C rs35551735 
26592764 C/T NO 
26592765 G/A rs190018049 
26593159 C/T rs17055838 
26593179 T/C rs111576315 




















26404986 0.015 11.52 0.015 11.52 
26405344 0.003 1.92 0.000 0.00 
26405508 0.066 50.56 0.046 35.20 
26434583 0.005 3.84 0.004 3.20 
26434626 0.014 10.88 0.005 3.84 
26434888 0.000 0 0.003 1.92 
26435213 0.008 6.4 0.007 5.12 
26435238 0.000 0 0.002 1.28 
26435451 0.006 4.48 0.003 1.92 
26436000 0.001 0.64 0.000 0.00 
26436034 0.067 51.2 0.053 40.96 
26436221 0.002 1.28 0.002 1.28 
26436344 0.002 1.28 0.000 0.00 
26436349 0.016 12.16 0.013 9.60 
26436351 0.003 2.56 0.000 0.00 
26436783 0.062 47.36 0.053 40.32 
26441264 0.013 9.6 0.016 12.16 
26441529 0.003 1.92 0.000 0.00 
26450631 0.003 1.92 0.000 0.00 
26450858 0.056 42.88 0.035 26.88 
26453162 0.005 3.84 0.003 1.92 
26454793 0.062 47.36 0.058 44.80 
26455539 0.000 0 0.047 35.84 
26455543 0.000 0 0.004 3.20 
26466011 0.000 0 0.013 9.60 
26466520 0.003 1.92 0.000 0.00 
26466789 0.001 0.64 0.000 0.00 
26466803 0.003 1.92 0.000 0.00 
26466877 0.072 55.04 0.067 51.20 
26467541 0.025 19.2 0.023 17.92 
26481666 0.002 1.28 0.000 0.00 
26484061 0.010 7.68 0.006 4.48 
26484081 0.002 1.28 0.000 0.00 
26484146 0.001 0.64 0.000 0.00 
26484392 0.000 0 0.003 1.92 
26484404 0.034 26.24 0.023 17.28 
26484426 0.027 20.48 0.043 32.64 
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26484652 0.002 1.28 0.003 1.92 
26485346 0.003 2.56 0.000 0.00 
26490251 0.002 1.64 0.002 1.64 
26498023 0.003 1.92 0.002 1.28 
26499497 0.057 43.52 0.034 26.24 
26501344 0.005 3.84 0.000 0.00 
26505307 0.003 1.92 0.002 1.28 
26513324 0.032 24.32 0.063 48.00 
26513364 0.013 9.6 0.013 10.24 
26513525 0.008 6.4 0.026 19.84 
26514054 0.016 12.16 0.028 21.76 
26514101 0.016 12.16 0.017 12.80 
26514144 0.017 12.8 0.016 12.16 
26514171 0.017 12.8 0.017 12.80 
26514231 0.067 51.2 0.054 41.60 
26515695 0.003 2.56 0.002 1.28 
26551529 0.003 1.92 0.000 0.00 
26564603 0.013 9.6 0.004 3.20 
26565429 0.000 0 0.003 1.92 
26565510 0.000 0 0.003 2.56 
26574356 0.051 39.04 0.042 32.00 
26576602 0.000 0 0.001 0.64 
26577324 0.022 16.64 0.021 16.00 
26577484 0.001 0.64 0.000 0.00 
26577795 0.000 0 0.001 0.64 
26577883 0.076 58.24 0.044 33.92 
26591911 0.018 14.08 0.033 24.96 
26592643 0.053 40.96 0.034 26.24 
26592764 0.016 12.16 0.016 12.16 
26592765 0.008 6.4 0.008 6.40 





Table 2.4: Variant enrichment analysis 
 
Table 2.4: After filtering the total SNVs for rare and functional variants, 
we analyzed 68 variants for enrichment in cases vs. controls. We 
identified a modest enrichment for rare variants in SZ cases at 1% and 
10% allele frequencies (p<4x10-4).   
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Figures: Chapter 2 
 
Figure 2.1: Strategy for DPYSL2 sequencing screen 
 
 
Figure 2.1: Strategy used for DPYSL2 sequencing screen. (1) AJ samples 
were normalized amd mixed into 12 pools of cases and 12 pools of 
controls, each with 32 samples. (2) For each pool I did 46 PCRs to span 
the 14 exons and 27 conserved non coding regions of DPYSL2. (3) The 
amplicons from the same pool were combined into 24 pools, each with 46 
amplicons. (4) The DNA from 24 pools were randomly fragmented, and 
used to generate 24 indexed libraries with Illumina’s Truseq kit.  Indexed 
library were quantified and combined together into 1 pool, which was 
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then sequenced on one lane on the Genome Analyzer to get 75 bp paired 
end reads.  
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Figure 2.2: Distribution of sequenced reads 
 
Figure 2.2: the distribution of reads for all 24 pools, separated by case 
and control pools. The differences in distribution between cases and 
controls are not significant, and the average number of reads per pool 




Figure 2.3: Distribution of identified variants 
 
 
Figure 2.3: A total of 286 SNVs were identified 286 using the manual 




Figure 2.4: Splicing analysis of 2 synonymous variants 
 
 
Figure 2.4: (A) Synonymous variants were predicted to alter binding of 
splicing factors. (B) PCR of carrier and non-carrier DNA obtained from 
lymphoblasts do not show altered splicing patterns.   
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We previously reported a schizophrenia-associated polymorphic CT di-
nucleotide repeat (DNR) at the 5’-UTR of DPYSL2 which responds to 
mTOR signaling with allelic differences. Using microarray analysis, we 
now show the DNR alleles interact differentially with specific proteins, 
including the mTOR-related protein HuD/ELAVL4. We confirm the 
differential binding to HuD and other known mTOR effectors by 
electrophoretic mobility shift assays. In HEK293 cells edited by 
CRISPR/Cas9 to carry the schizophrenia risk variant (13DNR) we 
observe significant reduction of the corresponding CRMP2 isoform and 
shortening of the cellular projections. Additionally, transcriptome 
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analysis by RNA-seq shows changes in 12.7% of expressed transcripts. 
These transcripts are enriched in immunity related genes, overlap 
significantly with those modified by the schizophrenia-associated gene, 
ZNF804A, and have a reverse expression signature from that seen with 
antipsychotic drugs. Our results support the functional importance of 






Family, twin, and adoption studies indicate a strong genetic 
contribution to risk for SZ 5,6, and in a linkage analysis of 57 multiplex 
pedigrees covering ~70% of the genome we previously identified region 
8p21-22 as a candidate SZ susceptibility locus (p=0.0001) 9. Our result 
was replicated by many other groups in different populations 10–12,36, and 
we followed it up with a targeted association study in an Ashkenazi 
Jewish population 13. We found the most significant SNP (rs12155555) 
was located ~5 kb upstream of DPYSL2B, and the strongest association 
signals from the fine mapping were located within or flanking the 
DPYSL2 gene 13. 
Subsequently, we identified multiple functional sequence variants 
in DPYSL2B, including a polymorphic CT di-nucleotide repeat (DNR) 
variant located within the gene's 5’-TOP tract that’s known to be 
regulated by the mTOR pathway 30,31,40,41. In Caucasians, this DNR most 
often comprises 11 CT repeats (11DNR).  The next most common allele 
caries 13 CT repeats (13DNR) and previously, in a small sequencing 
study, we found it at a frequency of ~14.5% in 93 healthy Caucasians 
and 29% in 46 Caucasians with SZ 42.  
The mTOR complex 1 (mTORC1) is a serine/threonine kinase 
complex that controls protein synthesis by phosphorylating downstream 
target effectors (Fig. 3.1). The complex owes its name to the potent 
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immunosuppressant drug, Rapamycin, which strongly inhibits mTORC1 
kinase activity. Canonical activation of mTORC1 results from an 
activation cascade of upstream proteins, including receptor tyrosine 
kinases (RTK), PI3K, and AKT. Once active, mTORC1 stimulates its 
downstream effector proteins, S6 and 4EBP, increasing ribosome 
biogenesis and mRNA translation, respectively 43–45. Fundamentally, 
mTOR activation boosts overall cell growth and metabolism, marking it 
as one of the better-known targets for cancer therapy 46–49. Increasingly 
however, the functions of mTOR have been extended to the development 
of the central nervous system, where mTOR is implicated in neuronal 
growth, maintenance, and proliferation 50–53. Perturbation of the mTOR 
signaling cascade can affect well known neurotransmitters involved in 
schizophrenia, such as serotonin, glutamate, and their receptors. Thus, 
disruption or dysfunction of this pathway could play a role in the risk to 
develop SZ 51. 
In this chapter, I report evidence that extend and strengthen the 
functionality of the risk 13DNR variant and its regulation by mTOR. 
First, in dual luciferase and polysome profiling assays we showed that 
the 13DNR variant significantly reduced expression at the translation 
level in HEK293 cells and in mouse primary cortical neurons. Further, in 
both cell types, there was a dose-dependent response of both DNR alleles 
to Rapamycin, an allosteric inhibitor mTOR 30. Then, we characterized 
the 5’UTR of the DPYSL2 transcript and its variants for interaction with 
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specific proteins, including mTOR effectors. Next, I showed that this 
naturally occurring DNR variant also has strong effects on DPYSL2 
regulation in its native context in the genome, with the longer repeat 
leading to significant reduction of the corresponding CRMP2 isoform in 
HEK293 cells. This change is accompanied by striking shortening of the 
natural HEK293 projections. Finally, we showed that significant changes 
in the transcriptome point to pathways implicated in SZ; these overlap 
with the changes observed with other SZ susceptibility genes, and 
oppose those observed by exposure to antipsychotics. 
 
Materials and Methods 
 
Cell culture  
 
HEK293: The human embryonic kidney cell line (HEK293; ATCC 
#CRL-1573) was cultured using standard protocols. Cells were 
maintained in Dulbecco’s Modified Eagle Medium (Invitrogen #11965-
084) with 10% fetal bovine serum (Sigma #12003C).  
 Mouse primary cortical neurons: I isolated and cultured mouse 
primary cortical neurons from E18 C57BL/6 mice using a previously 
described protocol 54. Cells were maintained in Neurobasal medium 
(Invitrogen # 21103049), 5% B-27 supplement (Thermo Fisher 
#17504044), 1% Penicillin-Streptomycin antibiotic (Thermo Fisher 
46 
 
#15140122), and 200mM L-glutamine (Thermo Fisher #25030081). Cells 
were grown on coverslips coated with poly-D lysine (Sigma #P0899) in 
borate buffer.  
Dual luciferase assays 
 
 To test the mTOR regulation in the 5’-UTR of DPYSL2, we 
transfected reporter constructs into HEK293 and mouse primary cortical 
neurons in the presence of increasing concentrations of Rapamycin. The 
reporter constructsfor the 11 and 13DNR alleles were the same ones 
generated previously 30. These were transfected into cell using 
Lipofectamine (Thermo Fisher #11668030) for 4 hours, after which the 
culture media was replaced to media containing the indicated 
concentrations of Rapamycin (Selleck Chem #S1039), dissolved in 
DMSO. After 24 hour exposure to the drug, we analyzed the cell lysates 
for luciferase activity.  
Protein interaction study 
 
Protein microarray: To study the differential binding of proteins 
to the DNR alleles, we performed protein microarrays. Fluorescently 
labeled RNA probes for the 11 and 13 DNRs were synthesized by IDT 
(Table 3.1). The probes were hybridized to the protein microarrays in 
duplicates and as described in previous protocol 55. The microarray chips 
contained >4,000 proteins, each of which is printed in duplicates, and 
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with multiple sets of positive control proteins. After hybridization, the 
protein chips were scanned with a GenePix 4000B scanner with 5-µm 
resolution detection at 635 nm. Microarray images then underwent 
corrections and normalizations, as specified in a previous protocol 56 . We 
selected an intensity cutoff value of Z-score > 9 to produce a significantly 
reduced list of “positive hits.” (Fig. 3.2) Proteins were considered to bind 
both alleles if the difference between the two allelic averages was less 
than two standard deviations. If the difference was greater than two 
standard deviations, then the protein was considered to bind 
preferentially to either the 11 or 13 DNR allele. 
EMSA: In order to confirm the differential binding of ELAVL4 and 
to test the binding of other mTOR signaling components such as S6K, 
4EBP and eIF4E, we performed electrophoretic mobility shift assays 
(EMSA). I utilized the same 3’ fluorescently labeled RNA probes from the 
microarray, but end-labeled the probes with radioactive γ–ATP-32 to the 
5’ end 57. The probes were purified (VWR SpinX Filters #29442-754, 
Clonetech Resin #631770), and precipitated overnight at -80C (3ul yeast 
tRNA, 6ul, NH4Ac, 24ul cold 100% EtOH). Radioactivity of the probe was 
quantified with a scintillation counter, and each probe was normalized to 
4,000 counts per minute (CPM).  
The radioactive RNA probes for each of the two DNR alleles were 
hybridized to commercially purified candidate binding proteins: S6 
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(Origene #TP317324), 4EBP (NovoProtein #C200), eIF4E (MyBioSource 
#MBS203380), and ELAVL4 (Origene #TP318612). Each probe was 
incubated on ice for 20 minutes in the following solution: 2X Probe 
Buffer (50% glycerol, 1M HEPES, 1M Tris-HCL, 0.5M EDTA, 100mM 
DTT, DEPC H2O, Bromophenol blue), BSA (10mg/ml, NEB #B9000s), 
Poly[d(I-C)] (1ug/mL, Roche #10108812001), DEPC H20, γ–ATP RNA 
probes (1ul at 4000 CPM), and purified proteins (1ug/ul). Each reaction 
was loaded into a precast 5% TBE gel (Bio-Rad #4565015) and 
electrophresed in 1x TBE buffer (Bio-Rad #1610733) at 150V for 30 
minutes, room temperature. The gel was air dried in clear cellophane 
(Bio-Rad #1651779) for 3 hours, and then exposed with autoradiography 
film (VWR # 8294985).  
CRISPR/Cas9 Targeting 
 
To study the effect of the DNR in its genomic context, we used the 
CRISPR/Cas9 system to create two isogenic cell lines with the 11 and 13 
DNR in HEK293 cells, which normally carry the 11 repeat DNR. Using 
the online tool provided by the Zhang Lab at MIT 58 (crispr.mit.edu), we 
designed three guide RNAs (gRNA) (Table 3.1). As a repair template to 
insert 2 CT repeats at the DNR region, we used the 13DNR reporter 
constructs from the dual-luciferase assay 30. The gRNA constructs were 
synthesized with the U6 Promoter and gRNA backbone via the gBlock® 
system by IDT 59.  
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We used lipfectamine (Thermo #11668027) to co-transfect the 
gRNA, the repair template, and a GFP tagged Cas9 nuclease (Addgene 
#44719) to HEK293 cells. Post transfection, the cells underwent 
fluorescence-assisted cell sorting into 96-well plates (1 cell/well). The 
single-cells were then expanded into clonal colonies, the DNA of which 
was used for sequencing to identify homozygotes for each allele (Fig. 3.6). 
We then selected 17 gene loci as candidates for off-target effects 
predicted by the online tool developed by the Zhang Lab at MIT to check 
for off-target effects. Using primers (Table 3.1) designed to capture and 
Sanger sequence 100-200 bp of these candidate loci, we identified no 
known off-target effects of the gene-editing scheme. 
Western blot 
 
We obtained cell lysates from the four 13DNR homozygote clones 
and four targeted 11DNR control clones, using 1X Passive Lysis Buffer 
(Promega #E1941). Protein was assayed with a colorimetric kit (Bio-Rad 
#5000001), quantified with spectrophotometry, and lysates were 
normalized to 20ug total protein.  
Protein was heated to 95C for 5 minutes in the following solution: 
2x loading buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 
0.004% bromophenol blue, 0.125 M Tris-HCl), H20. The samples were 
loaded into precast gels (Bio-Rad #4561083) and electrophresed at 120V 
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for 1 hour in 1x running buffer (Bio-Rad #1610732). The gel was then 
transferred to a PVDF membrane (Bio-Rad #1620177) via the semi-
dryelectrophoretic transfer cell (Bio-Rad #1703940) at 15V for 45 
minutes.  
After transfer, the membrane was blocked in 5% powder milk and 
1x TBS buffer (Bio-Rad #1706435) for >1 hour at room temperature. We 
then probed the membrane using rabbit anti-CRMP2 antibody at 1:5000 
(Sigma #C2993) and mouse anti-GAPDH at 1:4,000 (AbCam #ab9485) in 
1% milk overnight at 4C. Following wash steps in 1x TBS-T, we probed 
with mouse (AbCam #ab6728) and rabbit (Thermo #656120) HRP-
conjugated secondary antibodies at 1:10,000 in 1% milk for >2 hours at 
room temperature. After final washes, the membranes were exposed to 
chemiluminescence for HRP detection (Thermo #32132), and then 
exposed to autoradiography film. 
For Rapamycin exposures, we cultured the edited HEK293 cell in 
standard protocols with media containing 30nM Rapamycin 
(SelleckChem #S1039) for 24 hours. After drug exposure, we obtained 
the cell lysates as described above.  
Real-Time qPCR 
 
RNA was obtained from the selected CRISPR-edited clones using 
an RNeasy Mini Kit (Qiagen #74104). The RNA was reverse transcribed 
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into cDNA using qScript cDNA Supermix (Quanta Biosciences #84033). 
From this, we performed qPCR using PerfeCTa SYBR Green FastMix 
(Quanta Biosciences #95072) and primers for B-actin and DPYSL2. 
Samples were run on the 7900HT Sequence Detection System by Applied 
Biosystems. 
Immunofluorescence & Imaging 
 
Targeted HEK293 cells carrying the homozygous forms of the 11 
and 13 DNR alleles were grown on Poly-D Lysine (Sigma #P6407) coated 
coverslips in 12-well plates in standard HEK293 media at 37C. The 
media was changed every other day until day four (~75-85% confluency). 
Cells were washed twice with 1x Passive Buffered Saline, and then fixed 
in 4% paraformaldehyde for 15 minutes at room temperature. After 
removal of the paraformaldehyde and washing, the cells were incubated 
with 1mg/ml wheat germ agglutinin conjugated with Alexa Fluor 488 
(Thermo #W11261) at room temperature for 15 minutes. After removal 
and washing, the coverslips were mounted on slides with mounting 
media containing DAPI stain (Vectorlabs #H1200).  
Eighteen slides (nine from each cell group) were randomized and 
blinded before imaging. We had 4 clones per genotype and 3 slides per 
clone. We collected eight images for each slide. The images were analyzed 





We obtained cell pellets for the four 13DNR homozygous edited 
clones, and eight targeted 11DNR control clones. RNA was extracted from 
the cell pellets using an RNeasy Mini Kit (Qiagen #74104). The RNA was 
quantified and normalized to 500ng per sample and the samples were 
then sent to the Hopkins Core Facility. Agilent BioAnalyzer was used for 
quality control of the RNA prior to library creation, with a minimum RIN 
of 8.5. RiboMinus™ technology (ThermoFisher Scientific) was used to 
deplete ribosomal RNA molecules and Illumina’s TruSeq RNA v2 protocol 
was used to generate libraries.  Specifically, total RNA was converted to 
cDNA and size selected to 150 to 200 bp in length with 3' or 5' 
overhangs. End repair was performed where 3' to 5' exonuclease activity 
of enzymes removes 3' overhangs and the polymerase activity fills in the 
5' overhangs. An ‘A’ base was then added to the 3' end of the blunt 
phosphorylated DNA fragments which prepares the DNA fragments for 
ligation to the sequencing adapters and barcodes, which have a single ‘T’ 
base overhang at their 3' end. Ligated fragments were subsequently size 
selected through purification using SPRI beads and undergo PCR 
amplification techniques to prepare the ‘libraries’. The BioAnalyzer is 
used for quality control of the libraries to ensure adequate concentration 
and appropriate fragment size. The resulting library insert size was 120-
200bp with a median size of 150bp. DNA sequencing was performed on 
an Illumina® HiSeq 2500 instrument using standard protocols for paired 
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end 100bp sequencing. As per Illumina’s recommendation, 5% PhiX was 
added to each lane as a control, and to assist the analysis software with 
any library diversity issues. Primary Analysis was also performed in our 
core facility. Reads were processed through Illumina’s Real-Time Analysis 
(RTA) software generating base calls and corresponding base call quality 
scores. CIDRSeqSuite 7.1.0 was used to convert compressed bcl files into 
compressed fastq files. 
RNA-seq data analysis 
 
Forward and reverse raw reads separated by 12 barcode were 
received from our core facility showing no problems in data quality 
according to the accompanying FastQC reports 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Analysis 
was performed using the Tuxedo suite of programs including tophat for 
read mapping, cufflinks for transcript assembly and cuffdiff for transcript 
abundance comparisons as described previously 60. Following the Tuxedo 
pipeline the output was further processed using the R Bioconductor 









The DPYSL2 5'TOP sequence responds to mTOR  
 
The polymorphic DNR, located a 5’-TOP region, was previously 
shown to reduce DPYSL2 expression at the translational level. Because 
translation of 5’-TOP mRNAs is regulated by the mTOR pathway, we 
sought to explore how regulation of DPYSL2 expression may be 
influenced by mTOR signaling. We performed dual luciferase assays 
with HEK293 transfected the 11DNR and 13DNR in the absence and 
presence of Rapamycin, a potent mTOR inhibitor. In the absence of 
inhibitors, our results recapitulated previous data with the Risk allele 
showing ~2-3 -fold decrease in luciferase activity as compared with the 
WT allele (p<1.3 x 10-8). At concentrations of Rapamycin ranging from 
0-30 nM, the 13DNR allele showed lower luciferase expressions, as 
compared to the 11DNR allele.  Concentrations higher than 30nM 
substantially reduced luciferase expression for both alleles to a similar 
extent (Fig. 3.3A). The same trend was observed for mouse primary 
cortical neurons (Fig. 3.3B) From this we concluded that the differences 
in DPYSL2 expression between the two DNR alleles are likely mediated by 





The DNR alleles differentially bind TORC1 effectors and HuD 
 
To identify proteins binding to the 5’TOP sequence of DPYSL2, we 
used protein microarrays we have previously developed 55. We found 
exclusive binding of the 11DNR to 5 proteins: CHAMP1, a chromosome 
alignment phosphoprotein necessary for accurate mitotic division, and 
whose mutations have been recently linked to syndromic intellectual 
disability 61,62; CAST, a calpain inhibitor involved in proteolysis, and 
whose mutations have been implicated in Alzheimer’s disease 63,64; 
LMOD3, a member of the leiomodin family involved in skeletal muscle 
organization 65; TCEAL5, an X-linked transcription elongation factor 66; 
and ELAVL4 a well characterized ribosomal binding protein (RBP) with 
exclusive neuronal expression 67 (Table 3.2). ELAVL4, also known as 
Human Antigen D (HuD), is a member of a four-gene family of RBPs. Its 
known functions include the transport of target mRNAs from the nucleus 
to the cytoplasm and the triggering of neuronal differentiation 67–69. Most 
interestingly, recent evidence shows that like DPYSL2B, ELAVL4 is 
regulated by the mTOR pathway and promotes dendritic branching 70. 
Electrophoretic mobility shift assays (EMSA) with nuclear and 
whole cytosolic HEK293 cell extracts showed clear shifts for both oligos, 
indicating that the DNR probes have the capacity to bind to whole 
proteins (Fig. 3.4A). Then, in the presence of purified specific proteins, 
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the audiograph confirmed the differential binding of the 11DNR to 
ELAVL4 and to two additional proteins that are part of the mTOR 
downstream pathway, 4EBP and eIF4E (Fig. 3.4B). We noted the 
presence of an additional band migrating slightly higher than the main, 
unbound oligo band for the 11DNR allele. In subsequent additional 
experiments, we found that this band could be significantly diminished 
with heat treatment (Fig. 3.5A) immediately before loading (unfortunately 
this step cannot be incorporated in the EMSA experiment), suggesting 
potential dimers or folding. In later experiments using new batches of 
both RNA oligonucleotides, we observed the same bands for both 11DNR 
and 13DNR, and both could also be resolved with heat (Fig. 3.5B). We 
used these new oligos in additional EMSA experiments, repeating the 
initial and adding protein combinations (Fig. 3.5C). In those experiments 
the additional bands were present for both alleles, yet there was no 
difference from our original results. Given these experiments, we have 
excluded that this likely dimer formation or folding does not produce 
artifacts that could be responsible for the differences we see in binding. 
The 13DNR allele expresses reduced CRMP2 protein  
 
To test whether the differences we observed between the DNR 
alleles in reporter assays also apply to the translation of the DPYSL2BB 
transcript itself, we introduced the 13DNR allele into HEK293 cells using 
CRISPR/Cas9 genome editing technology 59. After targeting, we obtained 
57 
 
112 HEK293 cell clones that were successfully transfected and flow 
sorted for the presence of the co-transfected GFP tag. Of these, 4 clones 
(3.6%) were 13DNR homozygotes, and 3 clones were (2.7%) were 
heterozygotes (Fig. 3.6). The remainder clones were not modified at the 
target site, and were used as 11DNR controls. We selected 8 of these 
controls and the 4 homozygous 13DNR clones for further sequencing at 
17 candidate off-target gene sites, and identified no off-target mutations.  
Western blot analysis on 4 DNR11 and 4 DNR13 clones using a 
CRMP2 antibody recognizing all transcripts showed significant 
differences between the two isogenic cell groups (Fig. 3.7A, C). CRMP2B, 
migrating at 64 kDa, was significantly reduced in the 13DNR cells as 
compared to the 11DNR cells, both relative to CRMP2A migrating at 72 
kDa (p=6.5x10-6) and in absolute terms after normalization to GAPDH 
(p=0.0077) (Fig. 3.7A, C).  The absolute levels of CRMP2A were not 
affected (p=0.826). 
After exposure of the cells to 30nM Rapamycin, levels of CRMP2B 
protein in the 13DNR clones were reduced by nearly 8-fold (p=2.8x10-5) 
compared to only a 1.6-fold change for the 11DNR clones (p=0.0014) (Fig. 
3.7B, C). The reduction recapitulates our previous observations in 
applying Rapamycin to DPYSL2 promoter constructs driving luciferase 
expression 30. Overall, the results suggest that the 13DNR risk allele has 
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a weaker response to mTOR signaling, and is more sensitive to mTOR 
inhibition. 
In contrast to the protein results, the transcript profiles for 
DPYSL2 were not significantly different when measured by DPYSL2 
specific RT-PCR between the 11 and 13DNR cells, suggesting that the 
DNR affects primarily translation as expected for a variant in the 5’-TOP 
sequence in response to mTOR signaling.  
13DNR results in shorter cellular projections  
 
HEK cells naturally show neurite-like projections and have been 
suggested to have a neuronal lineage due to the original transformation 
methodology 71. They have also been found to express multiple neuron 
specific markers 71. Following the introduction of the 13DNR, we 
observed that the HEK293 projections appeared shorter in the 13DNR 
homozygous cells (Fig. 3.8A). This observation was confirmed by blinded 
measurements of projection length and comparison between homozygous 
11DNR cells (n=283) to homozygous 13DNR cells (n=348, p=10-42) using 
imageJ 72. The estimated length difference was ~2-fold (Fig. 3.8B).  
13DNR alters transcription, differences point to immunity genes 
 
The cell’s transcriptional output is the first level of response to any 
change, be it genetic or environmental. Having shown that the DNR 
variant has a strong effect on isoform abundance, we then asked whether 
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this change is important for the cell's homeostasis as reflected in its 
transcriptome, and whether the observed changes support a role in 
disease. We performed RNA-seq of the two isogenic cell groups acquiring 
~20 million paired reads for each of the 12 individually targeted clones 
(four with 13DNR and eight with 11DNR). The reads showed 85-90% 
unique alignment to the human genome. Initial quality control showed 
that all samples had similar fragments per kilobase per million (FPKM) 
distributions, but the 11DNR samples showed significantly higher 
variance across all FPKM levels (Fig. 3.9A). Additionally, a dendrogram 
based on all genes showed that two 11DNR samples (C2_5, C2_6) 
clustered together and separated early from all other samples, suggesting 
they are outliers (Fig. 3.9B). We considered that this may be either due to 
undetected off-target editing or to the chromosomal instability of this 
neoplastic cell line. Removing them restored the variance of the 
remaining six 11DNR samples to levels similar with the 13DNR. A new 
dendrogram using all genes on the new set of samples clustered the 
11DNR and 13DNR samples separately, showing that the genome wide 
expression profile differences were driven mostly by the genotype 
difference at the DPYSL2B DNR (Fig. 3.9C, D).  
From a total of 13,548 genes that were expressed in these cells, 
1,730 (12.7%) showed expression differences (FDR <0.05) between the 
11DNR and 13DNR groups. Of those, 802 were higher in 13DNR and 928 
in 11DNR. We used Panther bioinformatics to test whether the up- and 
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down-regulated genes showed enrichment for membership to different 
functional categories compared to the whole set of expressed genes. The 
most significant enrichment in biological processes was for genes 
expressed lower in the 13DNR that were often immune system process 
genes (2.04 fold, p = 2.6x10-7). This mirrors enrichments seen in SZ 
genes by both GWAS 73 and proteomics analyses 74–76. Genes expressing 
higher in 13DNR were strongly enriched for those encoding RNA binding 
proteins (2.6 fold, p=5.25x10-10). The complete results at p<0.01 are 
shown in Table 3.3. 
Genes changed by 13DNR overlap with genes changed by ZNF804A 
knockdown 
 
A previous study by Chen et al. 77 used a similar approach to ours 
on another SZ associated gene, ZNF804A. That study performed RNA-seq 
analysis after a knockdown approach to reduce the expression of, 
ZNF804A in neural progenitor cells derived from induced pluripotent 
stem cells. Reduced expression of ZNF804A has been reported to be the 
consequence of the SZ-associated allele of SNP rs1344706 in this gene 78. 
Despite significant differences between the studies, when we compared 
the reported up- or down-regulated genes by that study with ours, we 
found highly significant concordance and overlap. Specifically, of 57 
genes whose expression were significantly altered, 45 were in the same 
direction for both studies (binomial test p = 6.5x10-6). The overlap was 
significantly more than expected by chance for genes that were expressed 
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higher in the SZ risk condition, with 37 genes in common, more than 
twice more from the expected 16 (Fisher's exact test p= 1.6x10-6), but not 
in those expressed lower.  
13DNR transcription signatures are opposite to antipsychotic 
drugs 
 
The Connectivity Map (cmap) 79,80 is a collection of genome-wide 
expression data from human cell lines treated at varying concentrations 
in culture with 1,309 different bioactive small molecules, 18 of which are 
antipsychotics. Pattern-matching computational tools integrated in the 
cmap website (www.broadinstitute.org/cmap) allow the user to upload 
any gene signature (a set of up- and down-regulated genes) and compare 
it with the signatures of these small molecules for positive or negative 
correlations. We did this analysis for the transcriptional signature of the 
11DNR/13DNR variant and found that 3 of the top 10 cmap signatures 
most significantly matching the 13DNR group (all p < 2 x10-5), 3 were the 
antipsychotics Thioridazine, Trifluoperazine and Prochlorperazine. All 3 
had complimentary (i.e. opposite) signatures to the 13DNR allele. 
Interestingly, Rapamycin, the mTOR inhibitor, was also one of these top 








We demonstrate here that the DNR variant in the 5’UTR of the 
DPYSL2B transcript has strong effects on the expression of the 
corresponding protein isoform, and provide additional evidence that this 
is likely due to changes in its response to mTOR signaling. We find 
reduced binding to the 13DNR risk allele of two downstream mTOR 
effectors, 4E-BP and eIF4E, which may mediate these changes. In 
eukaryotes, phosphorylated 4E-BP releases eIF4E, allowing the de-
repressed factor to initiate cap-dependent translation 47,81. We also find 
that the binding of ELAVL4 to the DPYSL2 5'TOP alleles is markedly 
different comparing the 11DNR to the 13DNR alleles. The striking 
similarities in the functions of CRMP2 and ELAVL4 in neurons and their 
common regulation by mTOR make this an interesting lead for further 
research. 
The mTOR pathway promotes cell growth and division, and is 
widely known to be involved in cancer progression 46,82. Mounting 
evidence indicates that the mTOR pathway is also involved in brain 
plasticity, with aberrant signaling contributing to several 
neurodevelopmental disorders including schizophrenia 51–53. Our 
previous and current results support this hypothesis. We show that 
DPYSL2, a candidate schizophrenia susceptibility gene that’s involved in 
axonal growth and neuronal development, is regulated by mTOR. The 
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response to Rapamycin, the binding of mTOR effectors, and the 
transcriptome changes in the presence of the weaker binding allele all 
demonstrate the regulation of DPYSL2 translation by mTOR. The 
downstream effects of these changes provide candidate mechanisms for 
the connection to neurodevelopment and SZ.  
The link between mTOR and SZ risk is particularly interesting 
because it provides a potential explanation for environmental disease 
risk factors. The importance of starvation in SZ risk has been strongly 
established by studies in the Dutch and Chinese populations that 
experienced severe famines in the early to mid 20th century 83,84. In these 
populations, prenatal famines led to a 2-fold increased risk for 
schizophrenia. The mTOR pathway is highly sensitive to external 
environmental factors and, in particular, the availability of nutrients 
85,86. Starvation or otherwise malnutrition negatively affects the activity of 
this pathway, and could conceivably increase schizophrenia risk through 
changes in the regulation of genes involved in nervous system 
development such as DPYSL2. 
We used genome editing by CRISPR/Cas9, and created two 
isogenic cell lines differing genetically only in the DNR (CT) repeat length 
at the 5'UTR of DPYSL2. We observed that homozygotes for the 13DNR 
variant produced significantly less CRMP2B protein. Consistent with the 
known functions of CRMP2B, they also had significantly shorter cellular 
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projections. The transcriptome differences between 11 and 13DNR cells 
show that many genes are affected by this genetic change, presumably as 
a result of the change in CRMP2B production. These genes, listed in 
Supplementary table 1, provide important clues for unraveling the 
pathways involved in the function of CRMP2 and its possible connections 
to disease. 
In previous work 42, we found in a small sample that the 13DNR 
allele frequency was twice as high in SZ patients as in controls. To get a 
better estimate of the effect in a large sample we have identified two SNPs 
(rs367948, rs445678) that are in imperfect LD with this repeat, 
predicting the repeat genotypes in 41 of 42 individuals with data (data 
not shown). In the results of the PGC2 GWAS 73 these show a small 
increase in risk of 1.1 fold (p=0.04 - p=0.009 respectively in the same 
direction).  It is remarkable that a variant with such profound effects on 
the transcriptome and on cell morphology in cultured cells has such a 
small effect on the phenotype of the complete organism. This observation 
suggests that strong buffering mechanisms in the organism are involved 
to minimize the consequences of the DNR variant. This is not only good 
news for the carriers of such risk variants, but also for researchers 
exploring them, as it suggests that despite the small effect on risk typical 
of most GWAS-identified variants, their effects on isolated cellular models 
may be strong enough to measure and interpret. 
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In our transcriptome analyses we found significant changes in 
12.7% of transcripts resulting from the 13DNR. The specific genes 
affected by this variant provided three new lines of support for a 
connection between the gene and SZ. First, among down-regulated 
genes, the strongest enrichment was for genes involved in immunity. 
Although not directly intuitive, the immune system has been repeatedly 
implicated in SZ including the largest GWAS to date 73, proteomic studies 
23,87, gene expression studies 88, and reports for a role of 
infection/inflammation 89,90. Second, we saw a strong overlap and 
directional consistency between the genes affected by the SZ risk allele in 
our study and those affected by a similar perturbation in a previously 
published study of another SZ gene, ZNF804A. As more genes are 
studied, such overlaps should highlight the most important connections 
between risk variants and the corresponding pathways. 
Finally, in a survey of the 1,309 pharmaceutical compound-
induced expression change signatures in the connectivity map database, 
three antipsychotics raised to the top significance, all with signatures 
opposite to that of the 13DNR risk allele. This not only supports our 
hypothesis connecting the DNR to SZ but most importantly it indicates 
how cellular models might be useful in drug discovery. Other compounds 
on the top of the list would be interesting for further exploration of 
potential benefits against psychosis. 
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In conclusion, our experiments show that the SZ candidate gene 
transcript DPYSL2 is regulated by the mTOR pathway and this regulation 
is perturbed by a 5’UTR SZ-associated DNR, adding support for mTOR’s 
role in psychiatric disease. Further, our study of the transcriptome of 
genome-edited cells not only confirms the biological significance of the 
DNR, but it also provides additional links between DPYSL2 and 




Tables: Chapter 3 
 
Table 3.1: CRISPR/cas9 oligos 
gRNA sequences   Product size (bp) 
DNR_gRNA1 TCTTTTTTTTCCGCCCTAGC -- 
DNR_gRNA2 CTTTTTTTTCCGCCCTAGCT -- 
DNR_gRNA3 TTTTTTTTCCGCCCTAGCTG -- 
   Genotyping primers     
HekDNR_250_F TGCCTGAGAGGAAAGGGAGT 250 
HekDNR_250_R AATAGCAAGACCAGCGAAGC 250 
   Off-Target sequencing 
primers     




































































































 OTGprimer17F GTGGGTGACTGCTTGACTTT 138 
OTGprimer17R GACATGCCAAAAGGCCCTTG 
 













Figures: Chapter 3 
 
Figure 3.1: The mTOR pathway 
 
Figure 3.1: External stimuli such as nutrients and growth factors 
activate receptor tyrosine kinases (RTK), which then lead to the 
activation of downstream components, including phosphatidyl inositol-3- 
kinase (PI3K) complex and AKT. Once activated, mTORC1 
phosphorylates S6K, which increases ribosome biogenesis, and 4EBP1, 
which increases 5’ cap dependent mRNA translation. mTORC1 is highly 
sensitive to the immunosuppressant drug, Rapamycin. 
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Figure 3.2: Histogram distribution of Z scores 
 
Figure 3.2: Histogram distribution of positive protein bindings to each of 
the alleles (Red fluorophore = 11DNR, Green fluorophore = 13DNR). 





Figure 3.3: Rapamycin series in cultured cells 
 
 
Figure 3.3: Exposure of Rapamycin to HEK293 cultured cells (A) and 
mouse primary cortical neurons (B) showed dose-dependent responses 
for both DNR alleles. In both cell types, increased Rapamycin led to 
decrease in luciferase activity, and complete inhibition at 30nM for 








Figure 3.4: (A) Labeled DNR probes show clear shifts with the addition of 
the protein extracts, demonstrating the capacity to interact to whole 
proteins. (B) Labeled DNR probes and purified candidate binding 
proteins, confirming binding for 4EBP and eIF4E and ELAVL4. In all 




Figure 3.5: EMSAs resolving secondary structures in DNR probes 
  
 
Figure 3.5: (A) Denaturing conditions at high temperatures for the 
11DNR probe shows significant reduction of the secondary band. (B) New 
batch of DNR probes show secondary band for both alleles, which could 
also be diminished by heat treatment. (C) Validation of initial EMSA 
experiment and protein combinations with new DNR probes. No 
difference observed from our original results, despite additional band 
being present for both alleles.  
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Figure 3.6: Chromatographs of CRISPR-edited cell clones 
 
Figure 3.6: Chromatograph from Sanger sequencing confirming the 
genotypes of individual targeted clones at the DNR locus. Our targeting 
scheme yielded 4 clones that were 13DNR homozygous and 3 
heterozygotes while the rest were not modified at the target site despite 




Figure 3.7: Protein analysis of CRISPR-edited cell clones 
 
Figure 3.7: A) Western blots of targeted clones show significant 
differences in CRMP2B levels (64 kDa) between the two isogenic cell 
groups. (B) In the presence of 30 nM Rapamycin, CRMP2B is reduced for 
both cell groups, but most dramatically in the 13DNR cells. (C) 
Quantification of Western blots using Image J software. * p < 0.001; ** p 
< 2 x 10-5.  
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Figure 3.8: Morphological analysis of CRISPR-edited cell clones 
 
Figure 3.8: (A) Representative images of CRISPR-edited cells show 
morphological differences between the 11 and 13DNR cell groups. Cells 
stained for wheat germ agglutinin (green) and nuclei (blue). (B) 
Quantification of projection lengths between the two isogenic cell groups 




Figure 3.9: RNA-seq QC analyses 
 
 
Figure 3.9: Variance profiles and dendrograms based on all genes. C1 is 
13DNR, C2 is 11 DNR. (A) Variance profiles is significantly higher across 
all FPKM levels for the 11DNR. (B) Two 11DNR samples (C2_5, C2_6) 
cluster together and separate early from all other samples suggesting 
they are outliers. (C) Variance profiles for the two groups become similar 
after removal of the two outliers. (D) The dendogram now separates the 
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four 13DNR (C1) in one group, and six 11DNR (C2) in the other. Note 
that the numbering of the cell lines has now changed, C2_5 corresponds 








DPYSL2 encodes the CRMP2 protein that’s important for axon 
specification and development. This gene is a good SZ candidate for 
several reasons: (i) it is located within the 8p21 SZ susceptibility locus 
with the strongest linkage signal coming from a SNP located a few 
kilobases at the 3’ end of DPYSL2; (ii) its expression in the brain, and 
functions in axonal growth and neuronal migration are relevant to the 
study of SZ; (iii) it harbors the functional DNR that dramatically alters 
protein, morphology, and transcriptome levels in vitro; and, (iv), its 
regulation is linked to the mTOR pathway, which has been implicated in 
the pathology of neuropsychiatric diseases like SZ. To study the effects of 
this gene in vivo, we created a conditional knockout Dpysl2 mouse model 
that lacks the third exon of the gene in the forebrain. Preliminary 
behavioral tests in a small subset of heterozygous knockout mice (n = 10) 
show interesting increase in exploratory activity and reduction of anxiety 
levels. Additional behavioral testing and morphological analyses are 
necessary before we can confidently conclude the effects of Dpysl2 loss of 
function on mouse phenotypes. Nevertheless, the conditional Dpysl2 
knockout model is a powerful tool that will serve as the foundation for 





In this chapter, I describe the creation of the Dpysl2 knockout 
mouse model for the study of SZ. Modeling loss of function of a gene in 
an animal model has been an invaluable tool in the study of psychiatric 
diseases, as mice can model certain quantifiable facets of the disorders 
that mirror the human symptoms 91–94. Some of these genetic 
associations can be observed to alter behaviors, physiological, and 
morphological traits 95–97. As DPYSL2 is highly conserved and has known 
functions in axonogenesis 16,19,98, we hypothesized that loss of function of 
Dpysl2 in the mouse would result in phenotypic changes at the neuronal 
level and at the behavioral level.  
To our knowledge at the time of this writing, there have been no 
publications on a knockout model of Dpysl2 for the study of SZ. 
However, a targeted knock-in DPYSL2 mouse model was reported via 
substitution of an alanine in the place of a serine residue (Dpysl2-S522A) 
that is normally phosphorylated by Cdk5 19. Homozygous knock-in mice, 
designated Dpysl2ki/ki, were viable and their cortical cyto-architecture 
was normal. When these animals were bred to animals in which the 
Dpysl1 gene was disrupted to produce Dpysl1-/-; Dpysl2ki/ki double 
homozygote animals, the authors showed that cortical neurons had 
strikingly abnormal dendritic “curling” phenotypes. None of the single 
or double mutants have been characterized for any neurobehavioral 
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phenotypes. The lack of a knock-out Dpysl2 mouse model as well as the 
lack of a comprehensive phenotypic characterization of these animal 
models prompted us to create a knock-out mouse model of Dpysl2.   
To test the consequences of loss of function of Dpysl2, we took 
advantage of a commercially available knockout allele for Dpysl2 
(Dpysl2tm2e(KOMP)Wtsi), which at the time of this study, was available in 
embryonic stem (ES) cells via the UC Davis Knockout Mouse Project 
(KOMP) Repository. According to KOMP, the targeting event in this 
construct creates targeted ES cell clones without conditional potential 
through a gene-trapping event that introduces early polyadenylation 
signals, which interrupt transcription of the Dpysl2 gene (Fig. 4.1). As 
the targeting scheme involves sequences shared by all isoforms, removal 
of the floxed region is predicted to produce a truncated protein product of 
for Dpysl2A, Dpysl2B, and Dpysl2C. We planned to produce both 
heterozygous and homozygous targeted mice for functional testing. 
Also known as B6 albino, albino B6, B6(Cg)-Tyrc-2J/J mice have 
the C57BL/6J background but carry a mutation in the tyrosinase gene, 
which, in the homozygous form, results in white coat coloring. Following 
implantation and gestation, resulting offspring that are chimeric are 
easily identified by the black/white coat color. This method facilitates 
efficiency in the creation of knockout mice on the same C57BL/6J 
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genetic background as the ES cells, bypassing the need for multi-
generational backcrossing 99–101.  
With the help of the Johns Hopkins Transgenic Core, we obtained 
a colony of mice with positive germline transmission. However upon 
breeding these Dpysl2 +/neo; Tyr +/- mice to B6.C-Tg(CMV-cre) to remove 
the neo cassette, we observed complete perinatal lethality. Following 
extensive Southern blotting and sequencing of the entire targeted 
cassette, we identified an additional loxP site that flanked the 3’ end of 
exon 3. Though this was part of the original construct, KOMP reported 
this loxP was lost in the targeting event into ES cells, thus rendering the 
line non-conditional. Our sequencing studies showed that this additional 
loxP was retained and its presence confers conditional potential to the 
targeting allele. With this new knowledge, we revised our breeding 
scheme to remove the entire LacZ-neo cassette by mating to B6.C-
Tg(ACTFLPe) mice. The progeny of this cross, Dpysl2 +/lox were then 
mated to B6.C-Tg(Camk2a-cre) mice to produce mice with conditional 
knockout of Dpysl2 in the pyramidal neurons. We generated both 
heterozygous and homozygous mutants of these conditional knockouts 









We obtained C57BL/6N ES cells for the Dpysl2 knockout allele 
(DPYSL2tm2e(KOMP)Wtsi) from the KOMP repository (project ID CSD38021). 
The targeting construct has an SA-IRES-lacZ-pA cassette and a neo-pA 
cassette flanked by LoxP sites. Although the vector was designed to 
produce the knockout first allele, which has conditional potential, the 
only clones available were described as “tm2e,” meaning the third 3’ LoxP 
site was missing and contain the targeted non-conditional allele. The 
gene-trapping event in this allele introduces early polyadenylation 
signals, which interrupt transcription of the Dpysl2 gene, and is 
therefore predicted to result in complete loss of function of both 
Dpysl2A and Dpysl2B (Fig. 4.1). The ES cell clones were confirmed by 
genotyping protocol to be heterozygous for the mutant allele.  
Microinjection 
 
Confirmation of these lines was done through long PCR across the 
5’ and 3’ homology arm junctions and Southern blotting with probes 
specific for the 5’ flank and for the 3’ flank (Table 4.1). We next worked 
with the Hopkins Transgenic Core Laboratory for expansion of positive 
clones and karyotype analysis to rule out aneuploidy. The best growing 
ES clones passing these screens were then injected by the Johns 
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Hopkins Transgenic Core Laboratory, a service that yielded high-grade 
chimeric male mice on the C57BL/6 background heterozygous for the 
Tyrosinase deficiency for easy coat color screening. 
Breeding scheme 
 
We bred the black and white chimera mice that contained the 
knockout cells to albino C57BL/6 mice (JAX #000058) to obtain positive 
GLT progeny, which was indicated by a pure black coat color. Using PCR 
genotyping, we selected GLT positive mice heterozygous for the Dpysl2 
targeted allele as well as for the Tyrosinase mutation, Dpysl2 +/neo;Tyr +/-. 
Through an additional cross to wild-type C57BL/6 (JAX #000664), we 
obtained a line of mice heterozygous for the Dpysl2 targeted allele with 
no Tyrosinase deficiencies, Dpysl2 +/neo;Tyr +/+, henceforth abbreviated as 
Dpysl2 +/neo (Fig. 4.2). 
To remove the neo-resistance cassette, which has been reported to 
interfere with the targeting construct, we mated Dpysl2 +/neo mice to 
transgenic CMV-cre mice (JAX # 006054), which ubiquitously express 
the enzyme cre recombinase under the transcriptional control of a 
human cytomegalovirus minimal promoter. Using PCR genotyping, we 
screened for progeny that showed successful deletion of the neo-pA 
cassette that was flanked by LoxP sites. Because the progeny of this 
cross showed perinatal lethality due to an undisclosed LoxP site at the 3’ 
end of exon 3, we modified our breeding scheme to take advantage of the 
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conditional potential of this construct (Fig. 4.2). We mated Dpysl2 +/neo 
mice to transgenic ACTFLPe mice (JAX #005703), which ubiquitously 
express the enzyme FLP1 recombinase under the transcriptional control 
of the human actin B promoter. Presence of the FLP1 recombinase 
deleted the SA-IRES-lacZ-pA cassette and the neo-pA cassette that are 
flanked by FRT sites to yield mice with only the third Dpysl2 exon 
flanked by loxP sites, denoted as Dpysl2 +/lox. We crossed Dpysl2 +/lox to 
Dpysl2 +/lox mice to obtain a homozygous Dpysl2 lox/lox colony, with only 
loxP sites flanking the third exon on both alleles. As ubiquitous removal 
of the third exon likely contributed to perinatal deaths, we then mated 
Dpysl2 lox/lox mice to transgenic Camk2a-cre mice (JAX #005359), which 
express tissue-specific Cre recombinase under the direction of the 
calcium/calmodulin-dependent protein kinase II alpha (Camk2a) 
promoter. With this breeding scheme, we derived mice with two sets of 
genotypes. The first were heterozygous Dpysl2 exon3+/-;CamCre.Tg mice 
that also expressed Cre recombinase in the forebrain, which knocked out 
the third exon only in the pyramidal cell layer in the hippocampus. The 
second set of mice from this cross were of the genotype Dpysl2 +/lox, 
which were heterozygous for the Dpysl2 targeted allele but absent for the 
Cre recombinase, and therefore served as convenient wild-type littermate 






To confirm presence of the Dpysl2 targeted allele, we used primers 
(DPYSL2_neoF & DPYSL2_ttr) recommended by KOMP that span the end 
of the neo cassette into the 3’ homology arm (Table 4.1, Fig. 4.4). The 557 
bp fragment indicated the presence of the targeting cassette. To confirm 
deletion of the neo cassette with CMV-Cre mice, we designed primers 
(Floxed_2F & Floxed_2R) that span from the end of the lacZ cassette to 
the 3’ homology arm. The 2,419 bp fragment indicated the loxP sites 
along with the entire neo cassette were intact; however, absence of this 
fragment indicated the region was floxed (Table 4.1, Fig. 4.4). To confirm 
the integration of the targeting event into the mouse genome, we 
designed primers that tested the integration at the 5’ and 3’ end of the 
entire cassette. Integration at the 5’ end used primers (5'_Dpy_int_F & 
5'_Dpy_int_R) that resulted in a 5,240 bp fragment. Integration at the 3’ 
end used primers (3'_Dpy_int_F & 3'_Dpy_int_R) that resulted in a 5,703 
bp fragment (Table 4.1, Fig. 4.4). 
 To test for aberrant floxing due to the discovered third loxP site, we 
designed primers (Floxed_F1 & 3rdLoxP_R3) that spanned all three loxP 
sites. In this PCR, if the entire fragment was intact, the fragment size 
would be 8.6 kb. However, floxing combinations between the three loxP 
sites would result in smaller fragment sizes as follows: 6.6 kb if floxed 
between the first and second loxP sites; 7.6 kb if floxed between the 
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second and third loxP sites; 5.7kb if floxed between the first and third 
loxP sites (Table 4.1, Fig. 4.4). 
 Finally, to derive at the genotypes after crossing to ACTFLPe mice, 
we designed a double set of primers to reveal the genotype for both 
alleles. The first set of primers (lacZ_2F & lacZ_2R) span a 1.1 kb portion 
of the lacZ cassette, indicating presence of the targeted allele. The second 
set of primers (DPYSL2_F & DPYSL2_R) span from the 5’ homology arm 
to the 3’ homology arm, resulting in a 7.6 kb fragment for the targeted 
allele, and a fragment that’s 564 bp for the wild-type allele. Because PCR 
preferentially amplifies smaller amplicons, the 7.6 kb fragment is not 
visualized in a gel. After crossing to the ACTFLPe mice, excision at the 
FRT sites will remove 6.9 kb of genomic DNA, leaving a smaller 673 bp 
fragment to amplify from the DPYSL2_F/R primers, and no amplification 
for the lacZ_2F/R primer set. Thus, this PCR reveals several genotypes: 
wild-type Dpysl2+/+ (one 564 bp band), heterozygous Dpysl2 +/neo (one 
564 bp band, one 1.1 kb band), heterozygous Dpysl2 +/lox (one 564 bp 
band, one 673 bp band), and homozygous Dpysl2 lox/lox (one 673 bp 
band) (Table 4.1, Fig. 4.5).  
 To test the presence or absence of CMV-cre expression, we used 
primers Cre_1084 and Cre_1085. For Cam2ka-Cre, I used these primers 





 In order to investigate the cause of the perinatal deaths, we 
conducted southern blots to detect possible aberrant integration of the 
targeted cassette into the mouse genome. We designed three sets of 
probes specific to the 5’ homology arm (Probe 1), the lacZ cassette (Probe 
2), and the junction at the neo cassette and the 3’ homology arm (Probe 
3) (Fig. 4.6). For Probe 1, wild-type mice would show a 11.1 kb fragment, 
while heterozygous Dpysl2 +/neo mice would show a 13.4 kb fragment in 
addition to the 11.1 kb fragment. Probe 2 is specific to the inserted 
cassette, and would only show one 13.4 fragment to indicate presence of 
the lacZ in Dpysl2 +/neo mice. Similarly, Probe 3 shows as a 4.8 kb 
fragment only for the Dpysl2 +/neo mice.  
 For southern blots, we used DNA from 18 mice: 3 Dpysl2 +/neo 
parents; 4 Dpysl2 +/neo pups with the targeted allele and no Cre; 10 
Dpysl2 exon3 +/- pups with ubiquitous Cre expression; and, 1 Dpysl2 +/+ 
albino mouse as a negative control. The DNAs were digested with the 
restriction enzymes XhoI (NEB #R0146S) and AflII (NEB #R0520S) and 
loaded in a 0.9% agarose gel. The gel was denatured and transferred to a 
nylon membrane (Bio-Rad #1620177). Probes for the blot labeled with 
random primer labeling kits (Pharmacia Biotech #RPN1633), and P32 
dCTP. The membrane was hybridized to the probe using salmon sperm 
DNA and hybridization solution at 42 C overnight. The membrane was 
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washed and exposed on film (Sigma #350370). After autoradiography, 
membranes were boiled in stripping solution and used for hybridization 
with other probes.  
Behavioral tests 
 
To gather preliminary behavioral data on our set of Dpysl2 exon3 +/- 
mice and the control littermates Dpysl2 +/lox, we opted for a suite of well-
known baseline behavioral tests. This included the open field test for 
novelty-induced activity, Y-maze and spontaneous alternations for 
working memory, and the elevated plus maze (EPM) for anxiety levels. 
For these tests, we used mice 8-10 weeks old, 10 females and 3 males; 
however we excluded the 3 males from the end analysis. In addition, 
because testing anxiety can skew behavioral data, we performed the tests 
in order of increasing stress to the mouse, starting with open field, 
followed by spontaneous alternations, elevated plus maze, and ending 
with Y-maze. The genotypes of the mice were not revealed until after the 
data were collected. Brief descriptions of the tests are as follows: 
Open field test: This test measures locomotor activity and anxiety 
induced by novel environments 102,103. Each mouse was placed in a 
square chamber (16”x16”x16”) equipped with laser beams that recorded 
locomotor activity. After an acclimation period, we measured the 
frequency that a beam broke in 5-minute intervals. Mice were observed 
for a total of 45 minutes.  
92 
 
Spontaneous alternations: This test assesses working memory 
and tests the mouse’s ability to alternate of to all three different arms 
consecutively 104,105. For this, all three arms of the maze are open, and 
we manually recorded the number of triads (defined as entry into all 
three different arms in succession) in a period of five minutes. This was 
calculated as the number of triads divided by the maximum possible 
alternations (total alternations minus 2).  
Y-maze: This test also evaluates hippocampal-dependent learning 
and working memory and is focused on the mouse’s innate curiosity to 
explore new areas 106,107. Mice were conditioned to explore the maze for 5 
minutes with one random arm of the maze closed off. After 15 minutes, 
the mouse was returned to the maze with all three arms opened, and 
tested on the amount of time it spent in the previously closed arm. 
Entries and time spent in each arm was recorded via a camera.   
Elevated Plus Maze: This test measures anxiety levels, for which 
high anxiety would manifest as more time spent in the closed arm 108–110. 
The mouse was placed in the middle of the T-shaped contraption, and we 
recorded the time it spent in the open arm versus the closed arms of the 







Ubiquitous knockout of Dpysl2 results in perinatal lethality 
 
After obtaining heterozygous Dpysl2 +/neo mice with positive 
germline transmission, we intended remove the neo cassette, as this has 
been reported to interfere with the genetic background. However, we 
observed a high instance of perinatal lethality in pups produced by 
crossing heterozygous Dpysl2 +/neo mice to transgenic CMV-Cre mice. The 
perinatal deaths were not sex-specific, as deaths occurred for both males 
and female parental with the heterozygous Dpysl2 +/neo genotype (Fig. 
4.7). Necropsies and genotyping data were normal and did not point to a 
clear cause of death. We observed the deaths of the pups between 
postnatal day (P) 0 and P3, after which the entire litter was completely 
lost. Though the time of deaths varied, some pups that lived past P2 had 
the appearance of milk spots, suggesting that they were able to obtain 
nutrients from the mother. We observed bite wounds on some of the dead 
pups, but we could not ascertain whether the pups died first and were 
eaten, or the deaths were the result of infanticide by the mother. 
However, the fact that we observed the same pattern of mortality in many 
successive matings with the same parents indicated the deaths were not 
due to infanticide. Furthermore, we observed no evidence of perinatal 
deaths in the litters resulting from the matings between the heterozygous 
Dpysl2 +/neo mice to wild-type mice, and those from matings between the 
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CMV-Cre to wild-type mice. This line of evidence suggested the deaths 
were specific to the Dpysl2 targeted allele.  
Southern blots using probes specific to the Dpysl2 targeting 
cassette revealed abnormal DNA sequence pattern in the targeting 
construct for the dead pups (Fig. 4.8A, B, C). Sequence results for the ES 
cells and one chimeric mouse revealed the presence of a third LoxP site, 
oriented in the same direction as the other known LoxP recombination 
sites, located at the 3’ end of the homology arm. In three samples from 
mice that were heterozygous for the targeting allele and expressing the 
Cre enzyme, the Sanger traces showed deletion of large DNA segment 
between the first and third loxP sites. This was confirmed with the 
southern blot, which showed a band close to 5.7 kb and concordant with 
this pattern of floxing (Fig. 4.8B). From these results, we suspected 
deletion of the third exon of Dpysl2, even in heterozygous state, was 
incompatible with life. This hypothesis was confirmed, as once we 
amended the breeding scheme to create conditional Dpysl2 knockouts 
with Cam2ka-Cre mice, the deaths were no longer observed. Genotyping 
PCRs for mice obtained from this modified scheme showed the expected 
patterns of genomic deletions: Dpysl2+/+ (one 564 bp band), heterozygous 
Dpysl2 +/neo (one 564 bp band, one 1.1 kb band), heterozygous Dpysl2 
+/lox (one 564 bp band, one 673 bp band), and homozygous Dpysl2 lox/lox 
(one 673 bp band) (Fig. 4.5). 
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Baseline behavioral tests for Dpysl2 exon3 +/-  
 
As a preliminary investigation into the behavioral phenotypes of 
Dpysl2 conditional knockouts, we subjected a small cohort of female 
heterozygous Dpysl2 exon3 +/- mice (n = 3) and the wild-type littermates (n 
= 7) to four baseline behavioral tests. The first test, the open field, 
measured the mouse’s level of activity at the peripheral edges of the 
chamber and the center of the chamber as a proxy for anxiety levels 
induced by novel environment. Furthermore, this paradigm can also 
inform about the animals’ innate curiosity to explore novel environments. 
For this this test, central activity, peripheral activity, and the 
combination of both central and peripheral activity were non-significant 
(p >0.8). However, rearing, which is a measure of exploratory activity, 
was significant (p=0.016) with greater rearing activity for heterozygous 
knockouts. In subsequent tests, the mice showed no statistically 
significant differences for the spontaneous alternation (p = 0.79) or the Y-
maze (p = 0.37) (Fig. 4.9 A, B). The EPM test showed mild significance (p 
= 0.018) with heterozygous knockouts displaying less anxiety in the open 
arm (Fig. 4.9 C). We conclude from this that the sample sizes are too 
small for any steadfast interpretations and that additional testing in 






In this part of my thesis project, I aimed to explore the functional 
consequences of Dpysl2 loss of function in a mouse model. Although SZ 
is a human disease, mouse models can provide insight to certain facets 
of SZ-related symptoms, the results of which may point to genetic or 
other externally-induced alterations in the brain. Because Dpysl2 has 
vital functions in a biologically relevant organ, the brain, we suspected 
knocking out this gene in the mouse would alter the animals’ phenotype 
at some level. Indeed, our first breeding scheme to remove the neo 
cassette with CMV-Cre mice showed that Dpysl2 is essential for life, as 
knocking out just one copy of this gene resulted in perinatal lethality. 
That the deaths occurred between P0-P3 suggested early developmental 
failure, though the exact mechanism is yet unknown. Pups that died 
were observed to have normal parturition, normal feeding, and no other 
obvious anatomical defects. CRMP2 expression has been shown to be the 
highest during the first postnatal week when maturation of neurons and 
synaptic connections are most active 15,111. Thus, it is possible that the 
deaths could point to a mechanism of aberrant neurogenesis brought on 
by deletion of Dpysl2. However, further necropsies and molecular 
analyses are needed to rule out other causes of death and pinpoint the 
exact role of Dpysl2 in the death phenotype.  
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After discovering the presence of the third loxP site and the newly 
found conditional potential of this construct, we generated a line of 
heterozygous Dpysl2 exon3 +/- mice that had deletion of the gene in the 
pyramidal cells of the hippocampus. In the preliminary behavioral tests, 
these mice showed varying significance in phenotype alterations as 
compared to their wild-type littermates. In the paradigms that test 
spatial working memory and hippocampal-dependent learning, there was 
no statistical difference between the heterozygous mutants and the 
controls. However, the heterozygous conditional knockouts displayed 
statistically significant differences in the open-field test specific to rearing 
activity, and in the elevated plus maze test. It’s interesting that the 
significance overlap for these paradigms, as both measure the animal’s 
anxiety induced by open space and novel environments. That 
heterozygous mutants displayed less anxiety and increased exploratory 
drives seem counterintuitive but could suggest possible novel 
connections between the gene and brain behaviors. Nonetheless, these 
results are preliminary at best, as my sample size was extremely limited. 
Additional testing in more mice are needed before we can confidently 
conclude the effects of Dpysl2 loss of function in mouse behaviors.  
In summary, we’ve developed a conditional Dpysl2 knockout 
mouse model that has the potential to be a powerful tool in the study of 
SZ, and also genetics in general. To our knowledge at the time of this 
writing, no such mouse model exists for this gene in this background 
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strain. This model serves as the foundation for other future experiments 
that center on Dpysl2 loss of function. In extended behavioral 
phenotyping of these heterozygous and homozygous knockout mice, we 
can conclude if and how loss of Dpysl2 alters behaviors, and whether 
these changes could be proxy phenotypes to SZ-related symptoms. 
Morphological analysis of the brain at the gross and microscopic level 
could help us understand how Dpysl2 influences axonogenesis and brain 
development. It would also be informative to harvest the brains of 
heterozygous and homozygous mice at various stages of development to 
examine the consequences of Dpysl2 LOF on gene expression profiling, 
CNS development, and on neuronal morphology. In particular, this 
mutant mouse line offers the opportunity to culture primary cortical 
neurons carrying the loss-of-function mutation to study the role of 
Dpysl2 in neural polarity and axonogenesis in vitro. This set up could 
also allow the application of Rapamycin to assess Dpysl2 expression and 
mTOR inhibition in a more relevant cell model. Though the genetic 
design is different, it would be interesting to explore whether mTOR 
inhibition will accentuate these cells’ phenotypic manifestations similar 
to what we observed with HEK293 isogenic cells. Finally, if the Dpysl2 
knockout mice do show phenotypic changes consistent with our 
expectations of the gene, the model provides an excellent opportunity to 




Tables: Chapter 4 
Table 4.1: List of primers 
PCR name Primer ID Sequence Product (bp) 
    
CSD-Lac CSD-lacF  GCTACCATTACCAGTTGGTCTGG
TGTC  
690 
 CSD-Dpysl2-ttR  AACTTACACGAGGCAGCAAATTC
CC  
 
    
Neo CSD-neoF  GGGATCTCATGCTGGAGTTCTTC
G  
557 
 CSD-Dpysl2-ttR  AACTTACACGAGGCAGCAAATTC
CC  
 
    
5' integration 5'_Dpy_integrxn_F AGATTCCAGGCAGGGAGAAT 5240 
 5'_Dpy_integrxn_R GCCGCTTGTCCTCTTTGTTA  
    
3' integration 3'_Dpy_integrxn_F GGATTCAGGGCAGTCTGAAA 5703 
 3'_Dpy_integrxn_R TGGACAAAACCTTCCAATCC  
    






    




    
Floxing at 3rd 
loxP 
Floxed_F_1 GAATTCCAGCTGAGCGCCGGTC Variable 
 3rdLoxP_R3 AACCTCAGGTATAATACAGAGGG  
    
Nested Dpy CSD-Dpysl2-F  CCACATCTTCGGAGGTATAGGCA
GG  
Variable 
 CSD-Dpysl2-ttR  AACTTACACGAGGCAGCAAATTC
CC  
 







 Cre_1084 GCGGTCTGGCAGTAAAAACTATC 329 
 Cre_1085 GTGAAACAGCATTGCTGTCACTT  









    
Tyrosinase Tyr_F ATAGTCACTCCAGGGGTTGC 584 
 Tyr_R CAATGGGTCAACACCCAT  
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Figures: Chapter 4 
 
Figure 4.1: Dpysl2 targeting vector 
 
Figure 4.1: As described by KOMP, targeting vector originally contained 
3 loxP sites. However, it was reported that the third 3’ loxP site was lost 
in the recombination event, and so the construct works by early 




Figure 4.2: Initial breeding scheme to CMV-Cre mice 
 
Figure 4.2: C57BL/6 derived ES cell clones were expanded, karyotyped, 
and microinjected into the blastocyst of a pseudopregnant albino black6 
female. The high-grade chimeric male mice were then mated to albino 
Black 6 mice to obtain mice with positive germline transmission (Dpysl2 
+/neo). When these heterozygous mice were mated to CMV-cre mice, the 




Figure 4.3: Revised breeding scheme to produce conditional Dpysl2 
knockouts 
 
Figure 4.3: After learning about the intact third loxP site, we mated 
Dpysl2 +/neo mice to FLP-expressing mice to remove the entire lacZ and 
neo cassette, leaving only the third exon flanked by loxP sites. Resulting 
pups were crossed to each other to obtain homozygous floxed mice, 
which were then mated to Camk2a-Cre mice to obtain conditional 





Figure 4.4: PCR scheme to identify aberrant floxing 
 
Figure 4.4: To identify the cause of aberrant floxing, I designed primers 
that tested the pattern of genomic deletions in mice. LoxP sites indicated 
by red triangles. The lacZ and neo PCR primers demonstrated insertion 
of the cassette in the heterozygous Dpysl2 +/neo mice. Floxed PCR primers 
amplified 2.4 kb without deletion by Cre. In the presence of Cre, 6.6 kb 
would result if deletion occurred at the first and second LoxP; 7.6 if 
deletion occurred at the second and third LoxP; and ~5.7 kb if deletion 




Figure 4.5: PCR genotyping scheme 
 
  
Figure 4.5: PCR genotyping scheme from matings to Camk2a-Cre mce to 
identify heterozygous targeted mice: Dpysl2 +/neo (one 564 bp band, one 
1.1 kb band); heterozygous conditional knockouts: Dpysl2 +/lox (one 564 
bp band, one 673 bp band); homozygous conditional knockouts: Dpysl2 
lox/lox (one 673 bp band), and wild-type controls: Dpysl2+/+ (one 564 bp 
band). FRT sites are denoted as yellow triangles, and LoxP sites are 




Figure 4.6: Southern blot scheme 
 
Figure 4.6: For Probe 1, which was specific to the 5’ homology arm, wild-
type mice would show a 11.1 kb fragment, while heterozygous Dpysl2 
+/neo mice would show a 13.4 kb fragment in addition to the 11.1 kb 
fragment. Probe 2 was specific to the inserted LacZ cassette, and would 
only show one 13.4 fragment to indicate presence of the lacZ in Dpysl2 
+/neo mice. Similarly, Probe 3, specific to the junction at the neo cassette 
and the 3’ homology arm, would reveal a 4.8 kb fragment only for the 




Figure 4.7: Offspring deaths from matings to CMV-Cre mice 
  
Figure 4.7: Perinatal deaths occurred when Dpysl2 +/neo mice were 
crossed to CMV-Cre mice, regardless of the sex of the parents. Different 




Figure 4.8: Southern blots 
  
  
Figure 4.8: (A) Southern blots for the LacZ probe 1 confirmed 
heterozygous F0, F1 Dpysl2 +/neo mice without Cre showed a 13.4 kb 
fragment, while the wild-type (WT) mice showed a 11.1 kb fragment. 
Some F1 heterozygous mice with Cre expression showed differences in 
band patterns compared to the parentals. (B) Blots for neo probe 2, 
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specific to the inserted cassette, showed a 4.8 kb fragment only for the 




Figure 4.9: Dpysl2 knockout behavioral tests 
 
 
Figure 4.9: Baseline behavioral tests in conditional heterozygous 
knockout mice (n=3) compared to wild-type mice (n=7). (A) Spontaneous 
alternation paradigm showed no significant differences for memory 
deficits in either genotypes. (B) Y-maze paradigm did not show significant 
learning deficits in the heterozygous mutants. (C) Elevated plus maze 
showed heterozygous mutants spent more time in the open arm versus 
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